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CONTEXT 
CHBRP has identified only one anticancer medical device 
that meets the definitions in SB 746. This is based on 
CHBRP’s review of the literature as well as consultation 
with experts at the FDA and academic institutions. This 
device is known as Optune® and is used in the treatment 
of a type of brain cancer called glioblastoma multiforme 
(GBM). This device was approved by the FDA to treat 
patients with recurrent GBM in 2011 and patients newly 
diagnosed with GBM in 2015.1  
Cancers of the brain and central nervous system (CNS) 
make up 1.35% of all cancers. GBM is the third most 
common of all brain and CNS tumors (14.7%) and 
accounts for 47.7% of malignant brain tumors. It is 
estimated that 2,530 new cases of brain and CNS cancer 
cases will be diagnosed in California in 2019, and of 
these, approximately 1,200 (47.7%) are GBM. The 5-year 
survival rate for those diagnosed with GBM is the lowest 
of any cancer of the brain or CNS at approximately 5.6%. 
CHBRP’s analysis discusses the impact of mandating 
coverage for Optune®, which is a battery-operated, 
wearable, portable device that uses four adhesive patches 
to deliver low-intensity tumor treating fields (TTFields) to 
the GBM tumor. These patches are connected to the 
device and applied to the patient’s scalp. Although it is 
possible that other devices will be covered in the future, or 
that Optune® will be approved for the treatment of other 
types of cancer, for this analysis, CHBRP only describes 
current FDA-approved (as of March 2019) anticancer 
medical devices. 
CHBRP has assumed that SB 746 would be applicable to 
all health plans regulated by the California Department of 
Managed Health Care (DMHC) (including Medi-Cal 
Managed Care Plans) and policies regulated by the 
California Department of Insurance (CDI) as of January 1, 
2020.  
 
AT A GLANCE 
The version of California Senate Bill (SB) 746 analyzed 
by CHBRP would require that health plans and policies 
effective on or after January 1, 2020, that cover 
chemotherapy or radiation therapy for the treatment of 
cancer also cover anticancer medical devices that meet 
definitions set forth in SB 746. 
1. CHBRP estimates that, in 2020, all of the 24.5 
million Californians enrolled in state-regulated 
health insurance will have insurance subject to 
SB 746.  
2. Benefit coverage. Among enrollees that would 
be subject to SB 746, 91% have coverage for 
anticancer medical devices, which are 
categorized by health plans as durable medical 
equipment (DME). Because DME is already a 
covered benefit under California’s definition of 
essential health benefits (EHBs), SB 746 would 
not require coverage for a new state benefit 
mandate that appears to exceed the definition of 
EHBs. 
3. Utilization. It is estimated that there will be 56 
adult enrollees with coverage subject to SB 746 
using Optune® in the baseline year, and that 
utilization may increase by 10% (five users) 
postmandate.  
4. Expenditures. The cost of Optune® is $21,000 
per user per month, and the average length of 
use is 5.2 months. It is estimated that SB 746 
would increase total net annual expenditures by 
$648,000 or 0.0004%.  
5. Medical effectiveness. Adults with glioblastoma 
multiforme (GBM) using Optune® have 
increased overall survival and progression-free 
survival. 
6. Public health. There is no projected 
measurable public health impact at the 
population level due to the small estimated 
increase in utilization. 
7. Long-term impacts. The potential long-term 
impacts of SB 746 are unknown; larger impacts 
may occur in the long-term as more patients use 
the device and if the FDA approves more 
devices that are effective at treating cancer. 
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BILL SUMMARY  
SB 746 would require that health plans and policies 
effective on or after January 1, 2020, that cover 
chemotherapy or radiation therapy for the treatment of 
cancer also cover anticancer medical devices. The bill 
requires coverage of these medical devices only when the 
device has been approved by the FDA, is designed for 
use outside of a treatment facility, and is prescribed for the 
treatment of cancer based on medical necessity.   
Figure A shows how many Californians have health 
insurance that would be subject to SB 746. 
Figure A. Health Insurance in CA and SB 746 
 
Source: California Health Benefits Review Program, 2019. 
Notes: *Medicare beneficiaries, enrollees in self-insured products, etc. 
 
IMPACTS 
Benefit Coverage, Utilization, and Cost  
As noted above, this analysis focused on the use of 
Optune® to treat GBM because it is the only anticancer 
device on the market today that meets the specifications 
of SB 746. According to the bill, “anticancer medical 
device” means a medical device, including component 
parts, services, and supplies necessary for the effective 
use of the device.  
Benefit Coverage 
Among current enrollees with health insurance that would 
be subject to SB 746, 91% have coverage for Optune®, as 
determined by a survey of the largest (by enrollment) 
providers of health insurance in California. Responses to 
this survey represent 82% of enrollees with private market 
health insurance that can be subject to state mandates.  
Health plans and policies that cover Optune® do so under 
the durable medical equipment (DME) benefit, and any 
cost-sharing requirements for DME, such as deductibles, 
copayments, and coinsurance, apply to Optune®. 
Utilization 
It is estimated that there will be 1,200 new cases (3.21 
cases per 100,000 people) of GBM in California each 
year, with about 50% among adults aged 65 and over. SB 
746 would not affect coverage for most older adults with 
GBM because most have coverage through the Medicare 
program, which is not subject to state benefit mandates.  
Based on the age-adjusted incidence rate, CHBRP 
estimated that there will be 56 adult enrollees with 
coverage subject to SB 746 using Optune® in the baseline 
year. Even with insurance coverage for Optune®, patients 
may decide not to use it due to a variety of factors (e.g., 
not wanting to shave their head or wear a visible device, 
incompatibility with continuing to work), or providers may 
not offer it as a potential treatment.  
Patients who live longer due to the use of Optune® may 
incur use of other services (e.g., chemotherapy), but 
CHBRP did not include those in the utilization and cost 
impact estimates due to limitations of current claims data. 
Postmandate, it is estimated that the utilization of Optune® 
may increase 10% due to increased awareness and 
acceptance of the treatment by both providers and 
patients, which would result in five more users. 
Expenditures 
The cost of Optune® is $21,000, with an average cost paid 
by health plans and insurers of $18,624 per month per 
user, which includes component parts, services, and 
supplies necessary for the effective use of the device. The 
average length of Optune® use is 5.2 months. CHBRP 
estimates the average cost will be $96,845 per user. SB 
746 would increase total net annual expenditures by 
$648,000 or 0.0004%. This is due to a $717,000 increase 
in total health insurance premiums paid by employers and 
enrollees for newly covered benefits, adjusted by an 
increase in enrollee expenses for covered and/or 
noncovered benefits. CHBRP projects no change to 
copayments or coinsurance for those with coverage but 
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does project an increase in the utilization of Optune® and 
therefore an increase in overall enrollee cost sharing. 
Expenditure impacts are shown in Figure B. 
CHBRP does not project any cost offsets or savings in 
health care that would result postmandate since Optune® 
is used to complement other standard treatments. 
Figure B. Expenditure Impacts of SB 746  
 
Source: California Health Benefits Review Program, 2019.  
Medi-Cal 
CHBRP estimates there will be a $177,000 increase in 
expenditures for the 7.6 million Medi-Cal beneficiaries 
enrolled in DMHC-regulated plans. 
CalPERS 
CHBRP does not expect the impacts for CalPERS 
enrollees to be different from those for enrollees in other 
plans or policies.  
Number of Uninsured in California 
Because the change in average premiums does not 
exceed 1% for any market segment, CHBRP expects no 
measurable change in the number of uninsured persons 
due to the enactment of SB 746. 
Medical Effectiveness 
CHBRP’s review of the literature focused on the following 
outcomes: (1) overall survival, (2) progression-free 
survival, (3) quality of life and functional status, and (4) 
harms from the treatment. 
CHBRP found a preponderance of evidence that adults 
with GBM receiving Optune® have increased overall 
survival (i.e., the length of time during which the GBM 
does not get worse) compared to those who receive 
standard care (e.g., active chemotherapy such as 
temozolomide [TMZ]). There is limited evidence that 
Optune® increases progression-free survival among 
people with newly diagnosed GBM. Findings regarding the 
effects of Optune® on functional status and quality of life 
are inconclusive. There is limited evidence that using 
Optune® does not lead to more frequent or severe harms 
than standard of care; skin irritation or reaction was the 
most common harm identified. 
Public Health 
Despite a preponderance of evidence that Optune® is 
medically effective, CHBRP projects no measurable public 
health impact at the population level due to the small 
estimated increase in utilization (i.e., five new users). 
However, SB 746 would likely yield increased length of life 
among the additional five enrollees who would use 
Optune® in the treatment of GBM. 
Racial or ethnic disparities in the prevalence and 
treatment of GBM exist; however, CHBRP did not find 
evidence to suggest that SB 746 would impact utilization 
of Optune® differentially by race or ethnicity. Therefore, 
CHBRP projects no impact on racial or ethnic disparities 
related to GBM treatment and survival. 
Long-Term Impacts 
After the estimated increase in utilization in the first 12 
months, there is no indication in the research literature 
that the trend of utilization and incidence rate of enrollees 
with GBM will change over time. Because of this, CHBRP 
assumes that the 10% increase projected for Year 1 will 
persist in Year 2. However, in the long term, it is possible 
that Optune® could be improved and be utilized more 
widely as the treatment becomes more normalized and 
patient acceptance increases.  
There are several preliminary studies underway that 
assess the efficacy and safety of Optune® for other 
conditions and populations such as pediatric GBM, non-
small cell lung cancer, pancreatic cancer, ovarian cancer, 
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and cancer that has metastasized in the brain from other 
locations. It is uncertain what impact Optune® could have 
on survival rates for these cancers. There also may be 
more anticancer medical devices that come to the market 
in the future. If either of these things happens, the overall 
utilization of anticancer devices will increase, along with 
cost.  
The potential long-term impact of SB 746 is unknown, 
although it stands to reason that there is the potential for a 
larger impact in the long-term if the FDA approves 
Optune® to treat other cancers or approves other 
anticancer medical devices that are effective at treating 
cancer. 
Essential Health Benefits (EHBs) and the 
Affordable Care Act 
Anticancer medical devices are categorized by health 
plans as durable medical equipment (DME). Because 
DME is already a covered benefit under California’s 
definition of EHBs, SB 746 would not require coverage for 
a new state benefit mandate that appears to exceed the 
definition of EHBs. 
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The California Health Benefits Review Program (CHBRP) was established in 2002. As per its authorizing 
statute, CHBRP provides the California Legislature with independent analysis of the medical, financial, 
and public health impacts of proposed health insurance benefit-related legislation. The state funds 
CHBRP through an annual assessment on health plans and insurers in California.  
An analytic staff based at the University of California, Berkeley, supports a task force of faculty and 
research staff from multiple University of California campuses to complete each CHBRP analysis. A 
strict conflict-of-interest policy ensures that the analyses are undertaken without bias. A certified, 
independent actuary helps to estimate the financial impact. Content experts with comprehensive 
subject-matter expertise are consulted to provide essential background and input on the analytic 
approach for each report.  
More detailed information on CHBRP’s analysis methodology, authorizing statute, as well as all 
CHBRP reports and other publications are available at www.chbrp.org. 
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Table 1. SB 746 Impacts on Benefit Coverage, Utilization, and Cost, 2020 
    
  Baseline Postmandate Increase/ Decrease  
Change 
Postmandate 
Benefit Coverage         
    
Total enrollees with 
health insurance subject 
to state-level benefit 
mandates (a) 24,490,000 24,490,000 0 0% 
    
Total enrollees with 
health insurance subject 
to SB 746 24,490,000 24,490,000 0 0% 
    
Percentage of enrollees 
with coverage for anti-
cancer medical devices 91% 100% 9% 10% 
Utilization and Cost         
    Utilization per 1,000 0.012  0.013  0.001  10% 
  
  
Total enrollees subject 
to SB 746 using anti-
cancer medical devices 56  61  5  9% 
    
Average cost per 
enrollee using anti-
cancer medical devices 96,845  96,845  0.00 0% 
Expenditures         
  
Premium expenditures by 
payer         
    
Private employers for 
group insurance $86,438,375,000 $86,438,752,000 $377,000 0.0004% 
    
CalPERS HMO 
employer expenditures 
(c) $3,098,551,000 $3,098,562,000 $11,000 0.0004% 
    
Medi-Cal Managed Care 
Plan expenditures (d) $28,492,273,000 $28,492,450,000 $177,000 0.0006% 
    
Enrollees for individually 
purchased insurance $12,045,324,000 $12,045,397,000 $73,000 0.0006% 
    
     Individually 
purchased – outside 
exchange $2,486,222,000 $2,486,234,000 $12,000 0.0005% 
    
     Individually 
purchased – Covered 
California $9,559,102,000 $9,559,163,000 $61,000 0.0006% 
    
Enrollees with group 
insurance, CalPERS 
HMOs, Covered 
California, and Medi-Cal 
Managed Care (a) (b) $14,476,394,000 $14,476,472,000 $78,000 0.0005% 
  Enrollee expenses     
    
Enrollee out-of-pocket 
expenses for covered 
benefits (deductibles, 
copayments, etc.) $14,750,880,000 $14,750,812,000 -$68,000 -0.0005% 
    
Enrollee expenses for 
noncovered benefits (e) $0 $0 $0 0.00% 
  Total Expenditures  $159,301,797,000 $159,302,445,000 $648,000 0.0004% 
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Source: California Health Benefits Review Program, 2019. 
Notes: (a) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in 
employer-sponsored health insurance. This group includes commercial enrollees (including those associated with Covered 
California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.2  
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents. 
About one in five (20.5%) of these enrollees has a pharmacy benefit not subject to DMHC.3 CHBRP has projected no impact for 
those enrollees. However, CalPERS could, postmandate, require equivalent coverage for all its members (which could increase the 
total impact on CalPERS). 
(c) Enrollee premium expenditures include contributions by employees to employer-sponsored health insurance, health insurance 
purchased through Covered California, and contributions to Medi-Cal Managed Care. 
(d) Includes only expenses paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that 
are not currently covered by insurance. This only includes those expenses that would be newly covered postmandate. Other 
components of expenditures in this table include all health care services covered by insurance. 
(e) Although enrollees with newly compliant benefit coverage may have paid for some Optune® use before SB 746, CHBRP cannot 
estimate the frequency with which such situations may have occurred and therefore cannot estimate the related expense. 
Postmandate, such expenses would be eliminated, though enrollees with newly compliant benefit coverage might, postmandate, 
pay for some [tests/treatments/services] for which coverage is denied (through utilization management review), as some enrollees 
who always had compliant benefit coverage may have done and may continue to do, postmandate.  
Key: CalPERS  = California Public Employees’ Retirement System; CDI = California Department of Insurance; DMHC = Department 
of Managed Health Care; HMO = Health Maintenance Organizations 
                                                     
2 For more detail, see Estimates of Sources of Health Insurance in California, available at  
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.  
3 For more detail, see Estimates of Pharmacy Benefit Coverage, available at  
http://chbrp.com/analysis_methodology/cost_impact_analysis.php).  
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org 1 
POLICY CONTEXT 
The California Senate Committee on Health has requested that the California Health Benefits Review 
Program (CHBRP)4 conduct an evidence-based assessment of the medical, financial, and public health 
impacts of Senate Bill (SB) 746, Anticancer Medical Devices. 
Bill-Specific Analysis of SB 746, Anticancer Medical Devices 
Bill Language Summary 
SB 746 would require that health plans and policies effective on or after January 1, 2020, that cover 
chemotherapy or radiation therapy for the treatment of cancer also cover anticancer medical devices. It 
requires coverage of these medical devices only when the device has been approved by the FDA, is 
designed for use outside of a treatment facility, and is prescribed for the treatment of cancer based on 
medical necessity. The full text of SB 746 can be found in Appendix A. 
Relevant Populations 
If enacted, SB 746 would affect the health insurance of approximately 24.5 million enrollees (61.8% of all 
Californians). This represents 100% of the 24.5 million Californians who will have health insurance 
regulated by the state that may be subject to any state health benefit mandate law — health insurance 
regulated by the California Department of Managed Health Care (DMHC) or the California Department of 
Insurance (CDI). This includes Medi-Cal Managed Care Plan (MCP) enrollees.  
Interaction With Existing Requirements 
Health benefit mandates may interact and align with the following state and federal mandates or 
provisions. 
California Policy Landscape 
California law and regulations 
Cancer-related mandates 
There are currently seven state benefit mandates5 that require screening, diagnosis, and/or treatment for 
cancer. These include: 
• Breast cancer screening, diagnosis, and treatment;6 
• Cancer screening tests;7 
                                                     
4 CHBRP’s authorizing statute is available at http://www.chbrp.org/about_chbrp/index.php.  
5 A list of current health insurance benefit mandates in California state and Federal law is available under 
“Resources” at http://chbrp.com/other_publications/index.php.  
6 California Health and Safety Code 1367.6; California Insurance Code 10123.8. 
7 California Health and Safety Code 1367.665; California Insurance Code 10123.20. 
Analysis of California Senate Bill 746 
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• Cervical cancer screening;8 
• Mammography;9 
• Mastectomy and lymph node dissection (length of stay, complications, prostheses, reconstructive 
surgery);10 
• Patient care related to clinical trials for cancer;11 and 
• Prostate cancer screening.12 
SB 746 is not expected to interact with any of these mandates in the immediate future, since the only 
anticancer medical device identified by CHBRP at this time is for the treatment of a type of brain cancer, 
glioblastoma multiforme (GBM), which is not included in any of the above mandates. 
Through surveys and queries, CHBRP found that California health plans and insurers consider anticancer 
medical devices to fall under the durable medical equipment (DME) category. DME is defined as 
“equipment and supplies ordered by a health care provider for everyday or extended use.”13 CHBRP is 
not aware of any current or proposed benefit mandates related to DME. 
Similar requirements in other states 
CHBRP is not aware of similar benefit mandates in any other states related to anticancer medical 
devices. 
Federal Policy Landscape 
Affordable Care Act 
Essential Health Benefits 
State health insurance marketplaces, such as Covered California, are responsible for certifying and 
selling qualified health plans (QHPs) in the small-group and individual markets. QHPs are required to 
meet a minimum standard of benefits as defined by the ACA as essential health benefits (EHBs). In 
California, EHBs are related to the benefit coverage available in the Kaiser Foundation Health Plan Small 
Group Health Maintenance Organization (HMO) 30 plan, the state’s benchmark plan for federal 
EHBs.14,15 
                                                     
8 California Health and Safety Code 1367.66; California Insurance Code 10123.18. 
9 California Health and Safety Code 1367.65; California Insurance Code 10123.81. 
10 California Health and Safety Code 1367.635; California Insurance Code 10123.86. 
11 California Health and Safety Code 1370.6; California Insurance Code 10145.4. 
12 California Health and Safety Code 1367.64; California Insurance Code 10123.835. 
13 This definition of DME is available at http://www.healthcare.gov/glossary.   
14 The U.S. Department of Health and Human Services (HHS) has allowed each state to define its own EHBs for 
2014 and 2015 by selecting one of a set of specified benchmark plan options. CCIIO, Information on Essential Health 
Benefits Benchmark Plans. Available at: https://www.cms.gov/cciio/resources/data-resources/ehb.html.  
15 H&SC Section 1367.005; IC Section 10112.27. 
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California’s benchmark plan includes coverage for DME for home use and requires prior authorization for 
coverage.16 However, only about 5.1 million Californians are enrolled in a health plan or policy that is 
subject to EHBs.17 States may require QHPs to offer benefits that exceed EHBs.18 However, a state that 
chooses to do so must make payments to defray the cost of those additionally mandated benefits, either 
by paying the purchaser directly or by paying the QHP.19,20 State rules related to provider types, cost-
sharing, or reimbursement methods would not meet the definition of state benefit mandates that could 
exceed EHBs.21  
SB 746 would not require coverage for a new state benefit mandate that appears to exceed the definition 
of EHBs in California, since anticancer medical devices are categorized by health plans as DME, and 
DME is already a covered benefit under California’s definition of EHBs. 
Analytic Approach and Key Assumptions 
For the purposes of this analysis, CHBRP has assumed that there is only one anticancer medical device 
that meets the definitions in SB 746. This is based on CHBRP’s review of the literature as well as 
consultation with an expert at the FDA.22 This device is known as Optune® and is used in the treatment of 
GBM. This device was first approved by the FDA to treat patients with recurrent GBM in 2011 and 
patients newly diagnosed with GBM in 2015. 
This analysis will only discuss the impact of mandating coverage for Optune®.  
For the purposes of this analysis, CHBRP has assumed that SB 746 would be applicable to all DMHC- 
regulated plans (including Medi-Cal Managed Care Plans) and CDI-regulated policies as of January 1, 
2020.  
                                                     
16 A summary of benchmark plan requirements in California is available at http://www.cms.gov/ccio/resources/data-
resources/ehb.html.  
17 More information on California health insurance subject to EHBs is available in CHBRP’s “Estimates of Sources of 
Health Insurance in California” document under “Resources” at http://www.chbrp.org/other_publications/index.php.  
18 ACA Section 1311(d)(3). 
19 State benefit mandates enacted on or before December 31, 2011, may be included in a state’s EHBs, according to 
the U.S. Department of Health and Human Services (HHS). Patient Protection and Affordable Care Act: Standards 
Related to Essential Health Benefits, Actuarial Value, and Accreditation. Final Rule. Federal Register, Vol. 78, No. 37. 
February 25, 2013. Available at: www.gpo.gov\fdsys\pkg\FR-2013-02-25\pdf\2013-04084.pdf. 
20 However, as laid out in the Final Rule on EHBs HHS released in February 2013, state benefit mandates enacted 
on or before December 31, 2011, would be included in the state’s EHBs and there would be no requirement that the 
state defray the costs of those state mandated benefits. For state benefit mandates enacted after December 31, 
2011, that are identified as exceeding EHBs, the state would be required to defray the cost. 
21 Essential Health Benefits. Final Rule. A state’s health insurance marketplace would be responsible for determining 
when a state benefit mandate exceeds EHBs, and QHP issuers would be responsible for calculating the cost that 
must be defrayed. 
22 Personal communication with Jonathan S. Helfgott, formerly the Associate Director for Risk Science, within the 
Office of Scientific Investigations at FDA’s Center for Drug Evaluation & Research (CDER). Prior to joining CDER in 
2010, Mr. Helfgott worked at the FDA’s Center for Devices and Radiological Health (CDRH) within the Division of 
Bioresearch Monitoring (BIMO), March 2019. 
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BACKGROUND ON CANCER, GLIOBLASTOMA, AND 
RELATED TREATMENTS  
SB 746 requires health insurance coverage for FDA-approved devices for the treatment of cancer. 
CHBRP’s review of the literature as well as consultation with experts on FDA23 protocol found that 
currently there is only one such device, Optune®, which is used in the treatment of a type of brain cancer 
called glioblastoma multiforme (GBM). For the purposes of this analysis, CHBRP will only discuss the 
impact of mandating coverage for Optune®. Although it is possible that other devices will be covered in 
the future, or that Optune® will be approved for the treatment of other types of cancer, this analysis only 
describes current FDA-approved (as of March 2019) anticancer devices.  
This background section provides context for CHBRP’s analysis of SB 746 by discussing the incidence of 
cancer overall and GBM specifically, treatment options, and barriers to treatment with Optune®, as well as 
the social determinants of health that may influence treatment in California. Note that the following 
discussion broadly applies to the general population and includes persons with insurance subject to SB 
746 as well as the uninsured and those with health insurance not subject to state-regulated mandates, 
unless otherwise stated. 
Cancer 
Nearly one in two Californians born today will develop cancer at some point in his or her lifetime (CCR, 
2017). The treatment options for cancer depend on the type of cancer, as well as the stage of diagnosis, 
and include surgical removal, radiation treatment, and medications, including chemotherapy. In California, 
an estimated 186,920 cases of cancer will be diagnosed in 2019, whereas approximately 1.5 million 
Californians alive today have a history with the disease (ACS, 2019; CCR, 2017). In California, cancer is 
the second leading cause of death, accounting for 23% of all deaths, or approximately 60,590 deaths in 
2019 (ACS, 2017; ACS, 2019). Early diagnoses, through population-based screening, as well as 
advances in cancer treatment, have greatly improved survival rates of cancer patients (CCR, 2017). The 
5-year cancer survival rate varies dramatically based on the type of cancer, with a high of 99% for 
prostate cancer and a low of 8% for pancreatic cancer (ACS, 2018). 
Glioblastoma Multiforme (GBM) 
Cancers of the brain and central nervous system (CNS) make up 1.35% of all cancers (ACS, 2019). GBM 
is the third most common of all brain and CNS tumors (14.7%) and accounts for 47.7% of malignant brain 
tumors (Ostrom et al., 2018). It is estimated that there will be 2,530 new cases of brain and CNS cancer 
cases diagnosed in California in 2019 (ACS, 2019). Of these, approximately 1,200 (47.7% of 2,530) are 
GBM (ACS, 2019; Ostrom et al., 2018).  
The incidence rates for GBM for different groups in the United States are presented in Table 2. The 
overall annual adjusted incidence rate is 3.21 cases per 100,000 people (Ostrom et al., 2018). This differs 
by gender, where males have 1.58 times higher rates compared to females (Ostrom et al., 2018). Whites 
have the highest incidence rates compared to all other racial/ethnic groups. Incidence rates also increase 
with age, peaking in the 75–84 (15.13 per 100,000) and 65–74 (12.99 per 100,000) age groups. Those 
under age 20 had the lowest incidence rates (0.18 per 100,000) compared to all other age groups 
                                                     
23 Personal communication with Jonathan S. Helfgott, March 2019. 
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(Ostrom et al., 2018; Killion et al., 2018). The median age of diagnosis is age 65, with 49% of the cases of 
GBM diagnosed prior to age 65 (Ostrom et al., 2018).  
The 5-year survival rate for those diagnosed with GBM is the lowest of any cancer of the brain or CNS at 
approximately 5.6% (Ostrom et al., 2018). Table 2 also presents the overall 5-year survival rates for GBM 
for different demographic groups. While there were no differences in overall 5-year survival rates by 
gender, there were by age. Persons aged 0–19 and 20–44 had the highest survival rates (16.6% and 
19.1% respectively) compared to all other age groups, with the 5-year survival rate declining significantly 
in each older age group. In addition, whites had lower 5-year survival rates compared to other racial and 
ethnic groups, and those living in rural areas had lower survival rates compared to those living in urban 
areas. 
Treatment of GBM 
Standard treatment for GBM has been surgery followed by radio-chemotherapy, a combination of 
radiation and chemotherapy treatments (Kinzel et al., 2019). This standard treatment regimen leads to an 
average survival of 15–17 months (Kinzel et al., 2019). A newer adjuvant treatment option known as 
tumor treating fields (TTFields) is now recommended as part of standard treatment by the National 
Comprehensive Cancer Network (NCCN) Guidelines (Kinzel et al., 2019). NCCN recommends that 
providers offer people with GBM the option to add TTFields to radiation therapy and chemotherapy 
treatment if they have a score ≥60 on the Karnofsky Performance Status scale, a standardized measure 
of the ability of cancer patients to perform activities of daily living (NCCN, 2018).  
Optune® is the only TTFields device approved by the FDA to date. It is a battery-operated, wearable, and 
portable device that uses four adhesive patches to deliver low-intensity TTFields to the GBM tumor (see 
Figure 1). These patches are connected to the device and applied to the patient’s scalp. It is 
recommended that the patient wear Optune® at least 75% of the time (i.e., 18 hours a day). The 
effectiveness of this treatment in improving survival rates and other outcomes related to GBM is 
discussed in the Medical Effectiveness section. 
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Figure 1. Optune® Device by Novocure 
 
Source: https://www.harris.com/solution/cancer-treatment-with-novocure. Accessed on April 6, 2019. 
In deciding whether to utilize the Optune® treatment as part of the overall GBM treatment strategy, 
patients consider factors related to disruptions in daily routine such as the requirement to keep your head 
shaved, visibility of the device, the time and caregiver effort required to change the patches connected to 
the scalp every 3 to 4 days, increased sweating in warm temperatures, and physical difficulty in carrying 
the device (Onken et al., 2018). One study estimates that two-thirds of patients rejected therapy with 
Optune® when recommended by their physician (Onken et al., 2018). Reasons that patients have 
reported rejecting using Optune® for GBM include not wanting to shave their head or wear a visible 
device, or incompatibility with continuing to work (50%). Other reasons included lack of social support to 
change the patches (17%) and technical challenges (8%). More recent estimates indicate that 
acceptance rates have increased over time to 68% as more physicians and patients have become aware 
of Optune® and the most recent effectiveness data (Onken et al., 2018). 
Table 2. Incidence and 5-Year Survival Rates for GBM by Gender, Race, Age at Diagnosis and Location, 
United States 
 
Average Annual Adjusted 
Incidence Rates (per 
100,000) 
5-Year Survival Rates 
(Percent) 
Overall 3.21 (3.18-3.23) 5.6 (5.3-5.8) 
  Male 4.00 (3.95-4.04) 5.4 (5.0-5.8) 
  Female 2.53 (2.50-2.56) 5.3 (4.9-5.8) 
Age at Diagnosis   
  0-19 0.18 (0.17-0.20) 16.6 (13.2-20.4) 
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Average Annual Adjusted 
Incidence Rates (per 
100,000) 
5-Year Survival Rates 
(Percent) 
  20-34 0.46 (0.43-0.48) 19.1 (17.6-20.7) 
  35-44 1.25 (1.20-1.30) * 
  45-54 3.55 (3.47-3.63) 7.7 (7.0-8.5) 
  55-64 8.05 (7.92-8.17) 4.7 (4.2-5.2) 
  65-74 12.99 (12.79-13.2) 2.6 (2.2-3.0) 
  75-84 15.13 (14.84-15.43) 1.0 (0.7-1.3) 
  85+ 9.07 (8.73-9.42) * 
Race   
  White 3.47 (3.44-3.50) 5.1 (4.8-5.4) 
  Black 1.80 (1.73-1.86) 7.2 (5.8-8.7) 
  American Indian/Alaskan Native 1.43 (1.24-1.65) 7.9 (3.6-14.5) 
  Asian/Pacific Islander 1.57 (1.48-1.66) 8.7 (6.9-10.7) 
  Hispanic 2.4 (2.32-2.47) 8.1 (7.0-9.4) 
Location   
  Urban 3.13 (3.10-3.16) 5.8 (5.5-6.1) 
  Rural 3.03 (2.97-3.10) 3.9 (3.2-4.6) 
Source: Gittleman et al., 2018; Ostrom et al., 2018.  
Notes: Other than the incidence rate and survival rates for those aged 0–19, the remainder of the data in this table reflect persons 
aged 20 and older.  
*Five-year survival rates for ages 35–44 are presented in the cell above which represents data for ages 20–44; five-year survival 
rates for ages 85+ are included in the cell above which represents data for ages 75+.  
Disparities24 and Social Determinants of Health25 in Cancer Treatment 
Per statute, CHBRP includes discussion of disparities and social determinants of health (SDoH) as it 
relates to cancer treatment. Disparities are differences between groups that are modifiable. Although at 
this time, the only FDA-approved anticancer device, Optune®, is used to treat GBM, it is possible that in 
the future, there could be additional devices that would treat other forms of cancer. Therefore, since this 
                                                     
24 Several competing definitions of “health disparities” exist. CHBRP relies on the following definition: 
Health disparity is defined as the differences, whether unjust or not, in health status or outcomes within a population. 
Wyatt et al., 2016. 
25 CHBRP defines social determinants of health as conditions in which people are born, grow, live, work, learn, and 
age. These social determinants of health (economic factors, social factors, education, physical environment) are 
shaped by the distribution of money, power, and resources and impacted by policy (adapted from Healthy People 
2020, 2015; CDC, 2014). See CHBRP’s SDoH white paper for further information: 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php. 
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mandate may have a wider impact in the future, a discussion of the disparities in relation to cancer overall 
is presented below. 
The National Cancer Institute (NCI) notes that, across the United States, cancer disparities among 
racial/ethnic groups are closely associated with SDoH including income and built and social environments 
(e.g., stress, diet) (NCI, 2016). Numerous studies have documented that individuals from lower 
socioeconomic groups and specific racial and ethnic minorities have greater cancer risk and poorer 
cancer-related outcomes. This differential burden results in lower overall survival rates, a generally more 
advanced stage of cancer at time of diagnosis, and a higher eventual risk of death (Albain et al., 2009; 
Sloane, 2009). Compared with whites, African Americans have poorer survival once cancer is diagnosed. 
Five-year relative survival is lower in blacks than in whites within every stratum of stage of diagnosis for 
nearly every cancer site (Ward et al., 2004). As cancer treatments become more sophisticated, the 
disparity between whites and non-whites is likely to widen (Meropol and Schulman, 2007). This is likely 
because disparities in socioeconomic status lead to disparities in access to new medical advances and 
ultimately in health status. Therefore, medical advances (such as anticancer medical devices) may 
exacerbate disparities in relative racial/ethnic cancer survival rates (Tehranifar et al., 2009).  
While ethnic minorities have higher rates of cancer overall and lower survival rates, a different pattern is 
seen when looking at GBM specifically. As presented in Table 2, analysis of the NCI Surveillance, 
Epidemiology, and End Results (SEER) database found that non-Hispanic whites have higher rates of 
incidence of GBM as well as lower 5-year survival rates compared to other racial/ethnic groups (Ostrom 
et al., 2018). In addition, a study using that same dataset adjusted for other factors such as age, gender, 
insurance status, location and size of the tumor, and type of surgery, and found that Asians and Pacific 
Islanders have better survival rates compared to non-Hispanic whites (Bohn et al., 2018). In terms of 
treatment for GBM, one study found that factors associated with not receiving therapy for GBM included 
being female, black, Hispanic, and of older age (Dressler et al., 2019). 
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MEDICAL EFFECTIVENESS 
As noted in the Background section, the FDA has approved one anticancer medical device that CHBRP 
believes fits SB 746’s definition of an anticancer medical device: Optune®. This device was first approved 
by the FDA in 2011 to treat patients with recurrent glioblastoma multiforme (GBM); further approval was 
granted in 2015 to treat patients newly diagnosed with GBM. Optune® delivers low-intensity tumor treating 
fields (TTFields) to the GBM tumor. TTFields are alternating electrical fields that pulse through the skin of 
the patient’s scalp and disrupt the cancer cells’ ability to divide and spread. 
The medical effectiveness review summarizes findings from evidence26 on the effectiveness of Optune® 
to treat GBM in adults, for which the device is FDA-approved. Although several preliminary studies are 
underway that assess the efficacy and safety of Optune® for pediatric GBM (Green et al., 2017), non-
small cell lung cancer (Pless et al., 2013), pancreatic cancer (Rivera et al., 2019), and ovarian carcinoma 
(Vergote et al., 2018), CHBRP did not include these studies in its review because the FDA has not 
approved Optune® for treatment of these populations. Patients are currently being recruited into a pilot 
trial (Drexell Hunter Boggs) and a phase III randomized clinical trial (Novocure Ltd.) to study the effects of 
TTFields on brain metastases from lung cancer. Descriptions of both of these studies can be found at 
ClinicalTrials.gov. They are not included in CHBRP’s analysis because no findings have been published 
to date. 
Research Approach and Methods 
Studies of Optune® were identified through searches of PubMed, the Cochrane Library, Web of Science, 
Embase, and Scopus. The search was limited to abstracts of studies published in English from 2010 to 
present because Optune® did not receive FDA approval until 2011. 
The literature review returned abstracts for 288 articles, of which nine studies met the inclusion criteria in 
the medical effectiveness review. Articles were excluded for several reasons, with the most common ones 
being that the studies did not report findings from a research study, they did not address the effectiveness 
of Optune®, they illustrated the mechanism of action of TTFields (i.e., did not address efficacy of 
TTFields), or they were performed using computer-generated models.  
The conclusions below are based on the best available evidence from published peer-reviewed and grey 
literature. 
Key Questions 
1. What is the impact of Optune® on health outcomes (e.g., mortality, remission, quality of life)? 
2. Does the rate of compliance with Optune® (i.e., percent of hours in the day during which a person 
wears Optune®) affect the device’s effectiveness? 
3. Are there harms associated with using Optune®? 
                                                     
26 Much of the discussion below is focused on reviews of available literature. However, as noted on page 11 of the 
Medical Effectiveness analysis and research approach document (posted here), in the absence of “fully-applicable to 
the analysis” peer-reviewed literature on well-designed randomized controlled trials (RCTs), CHBRP’s hierarchy of 
evidence allows for the inclusion of other evidence. 
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Methodological Considerations 
Nine articles were determined to be relevant to SB 746. Two articles — Stupp et al., 2017 (EF-14 trial); 
and Stupp et al., 2012 (EF-11 trial) — presented findings from the foundational randomized controlled 
trials (RCTs) that analyzed the effectiveness of Optune® on GBM. Both of these RCTs were funded by 
Novocure Ltd., the manufacturer of Optune®. Six studies (Kanner et al., 2014; Kesari and Ram 2017; 
Stupp et al., 2015; Taphoorn et al., 2018; Toms et al., 2019; and Zhu et al., 2017) were either interim or 
post-hoc analyses of the two foundational studies. One study analyzed data from a patient registry of 
people with recurrent GBM who received Optune® outside of a clinical trial (Mrugala et al., 2014). Table 3 
summarizes key attributes of these studies, including what foundational RCT the analysis is based on and 
how the study outcome(s) differed. 
Table 3. Key Attributes of Studies Included in the Medical Effectiveness Review 
Study Study Participants Study Design Study Outcome(s) 
Stupp et al., 
2012 (EF-11 
RCT) 
237 patients 18+ years old with 
histologically confirmed recurrent 
GBM who had completed 
radiotherapy with and without 
concomitant and/or adjuvant 
temozolomide (TMZ) 
RCT with 1:1 randomization to 
TTFields alone (n=120) or active 
chemotherapy (n=117). Study was 
conducted at 28 institutions 
Primary: overall survival 
Secondary: progression-
free survival, quality of 
life, and safety 
Kanner et al., 
2014 See EF-11 RCT 
Post-hoc analysis of EF-11 RCT data. 
Instead of analyzing the intent-to-treat 
(ITT) population, analyzed the “as 
treated” groups 
Overall survival in 
subgroups of patients 
Stupp et al., 
2017 (EF-14 
RCT) 
695 patients 18+ years old with 
newly diagnosed GBM who had 
completed standard radiotherapy 
with concomitant TMZ 
RCT with 2:1 randomization to 
TTFields+TMZ (n=466) or TMZ alone 
(n=229). Study was conducted at 83 
centers 
Primary: progression-free 
survival 
Secondary: overall 
survival, adverse events 
Stupp et al., 
2015 See EF-14 RCT 
Interim analysis of EF-14 RCT 
conducted on the first 315 patients 
after at least 18 months of follow-up 
Primary: progression-free 
survival 
Secondary: overall 
survival 
Kesari and 
Ram, 2017 See EF-14 RCT Post-hoc analysis of EF-14 RCT 
Overall survival rates from 
day of first progression 
until death or censored 
event 
Taphoorn et al., 
2018 See EF-14 RCT 
Secondary analysis of data from the 
EF-14 RCT 
Quality of life, 
deterioration-free survival, 
and time to deterioration 
Toms et al., 
2019 See EF-14 RCT 
Sub-group analysis of data from the 
EF-14 RCT. Correlated TTFields 
Progression-free survival 
and overall survival given 
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Study Study Participants Study Design Study Outcome(s) 
compliance with progression-free 
survival and overall survival vs. TMZ 
alone 
the percentage of monthly 
treatment compliance 
Zhu et al., 2017 See EF-14 RCT 
Interim analysis of EF-14 RCT 
conducted on the first 315 patients 
after at least 18 months of follow-up 
Quality of life at 3, 6, and 
9 months out from 
baseline; cognitive status; 
functional status 
Mrugala et al., 
2014 
Patient Registry Dataset (PRiDe) 
of recurrent GBM patients who 
received Optune® in a clinical 
practice setting  
Outcomes of patients in PRiDe were 
compared to outcomes of patients in 
both groups of the EF-11 RCT using 
Kaplan-Meier curve estimates 
Primary: overall survival 
Secondary: adverse 
events 
Source: Kanner et al., 2014; Kesari and Ram, 2017; Mrugala et al., 2014; Stupp et al., 2012; Stupp et al., 2015; 
Stupp et al., 2017; Taphoorn et al., 2018; Toms et al., 2019; Zhu et al., 2017 
Key: GBM = glioblastoma multiforme; PRiDe = Patient Registry Dataset; RCT = randomized controlled trial; TTFields = tumor 
treating fields; TMZ = temozolomide 
Although both foundational studies were RCTs, they have some limitations. The design of the RCTs was 
such that patients in the intervention group received Optune® alone or plus chemotherapy, and patients in 
the control group received chemotherapy. This design did not blind participants to the type of treatment 
they received, which may bias the estimate of the size of the effect of Optune®. The research design 
would have been stronger if patients in the control group were fitted with a sham TTFields device, 
because this would have enabled the researchers to estimate the placebo effect associated with the 
device. 
Outcomes Assessed 
The nine articles included in CHBRP’s review assessed the following outcomes: (1) overall survival; (2) 
progression-free survival; (3) quality of life and functional status; and (4) harms from the treatment. 
Study Findings27 
CHBRP found a preponderance of evidence that persons receiving Optune® have increased overall 
survival (i.e., the length of time during which the GBM does not get worse) compared to persons who 
receive standard care (e.g., active chemotherapy such as TMZ). There is limited evidence that Optune® 
increases progression-free survival among people with newly diagnosed GBM. Findings regarding 
improvements in functional status and quality of life measurements are inconclusive. There is limited 
evidence that using Optune® does not lead to more frequent or severe harms than standard of care. 
                                                     
27 The figures in this section summarize CHBRP’s findings regarding the strength of the evidence for the effects of 
Optune® on GBM addressed by SB 746. For test, treatments, and services for which CHBRP concludes that there is 
clear and convincing, preponderance, limited, or inconclusive evidence, the placement of the highlighted box 
indicates the strength of the evidence. If CHBRP concludes that evidence is insufficient, a figure that states 
“Insufficient Evidence” will be presented. 
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Overall Survival  
Seven articles presented findings from the EF-11 and EF-14 RCTs regarding the impact of Optune® on 
overall survival for patients with GBM. The first article published regarding findings from EF-11 RCT 
examined an intent to treat (ITT) population (i.e., all randomized patients regardless of whether or not 
they received the treatment) of patients with recurrent GBM. Stupp et al. (2012) found no statistically 
significant improvement in the median length of overall survival among those in the intervention group 
versus those in the control group (active chemotherapy according to the physician’s best choice). 
Persons in the intervention and control groups had median overall survival of 6.6 months and 6.0 months, 
respectively. A post-hoc analysis of this study that focused on the “as treated” population, which excluded 
27 individuals because they did not receive at least one course of Optune®, found that the median overall 
survival for patients receiving at least one course of Optune® was significantly longer than for those who 
received chemotherapy (7.7 vs. 5.9 months) (Kanner et al., 2014). Another study that compared data 
from the Patient Registry Dataset (PRiDe), a database that captures “real-world” clinical use of Optune®, 
to the EF-11 RCT results found that overall survival rates for Optune® using real-world data were 
significantly longer than the rates found in the RCT (Mrugala et al., 2014). The median length of overall 
survival for patients using Optune® outside of the RCT was 9.6 months. However, this estimate of median 
overall survival from this observational study may be biased upward because patients who are followed 
more closely and receive better care to treat a recurrence of GBM may be more likely to be offered 
Optune® than other people with GBM who receive care outside of clinical trials. In addition, the percent of 
patients enrolled in the PRiDe study who were treated for a first recurrence of GBM was larger than the 
percent of patients in the EF-11 RCT who were treated for a first recurrence (Mrugala et al., 2014). This 
finding suggests that the impact of Optune® on overall survival may be greater among persons treated for 
a first recurrence of GBM than for subsequent recurrences.  
The EF-14 RCT (Stupp et al., 2017) studied overall survival for patients newly diagnosed with GBM 
randomized to receive Optune® plus TMZ versus participants receiving TMZ alone. Those in the ITT 
population who received Optune® had longer median overall survival than those who did not (20.9 months 
versus 16.0 months). Stupp et al. (2015) found a similar result in their interim analysis of the same RCT. 
For the “as treated” population, the interim analysis found that those treated with Optune® in addition to 
TMZ had a median length of overall survival of 20.5 months versus 15.6 months among those who 
received TMZ alone. In the ITT population, the median overall survival was 19.6 months in the Optune® 
plus TMZ group and 16.6 months in the TMZ alone group. Kesari and Ram (2017) and Toms et al. (2019) 
also conducted analyses on the effect of Optune® on overall survival among patients enrolled in this RCT. 
Kesari and Ram (2017) performed a post-hoc analysis of the overall length of survival for RCT 
participants from the day of first progression. Patients treated with Optune® in addition to TMZ versus 
TMZ alone lived statistically significantly longer following the first day of progression — 11.8 months 
versus 9.2 months.  
Toms et al. (2019), Kanner et al. (2014), and Mrugala et al. (2014) found that median overall survival was 
longer among patient subgroups who demonstrated greater compliance with their Optune® treatment 
regimen. Toms et al. (2019) looked at EF-14 RCT participants whose treatment compliance rate was at 
least 50% (i.e., the participant used Optune® at least 12 hours per day); they concluded that those 
participants in the Optune® plus TMZ group had a longer median overall length of survival than the TMZ 
only group with maximal survival benefit in the >90% compliance group. The median overall length of 
survival in the Optune® plus TMZ group with >90% compliance was 24.9 months compared to 16.0 
months in the TMZ alone group with >90% compliance. Kanner et al. (2014) found that the median overall 
length of survival was significantly longer in patients receiving Optune® with a maximal monthly 
compliance rate of greater than or equal to 75% (i.e., used Optune® for at least 18 hours daily) versus 
those with a less than 75% compliance rate (7.7 months vs. 4.5 months, p=0.042). The study also 
showed a significant trend for improved median overall survival with higher compliance (p=0.039). 
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Mrugala et al. (2014) found a significant difference in median overall survival in patients with a daily 
compliance rate of greater than or equal to 75% versus those with a less than 75% compliance rate (13.5 
months vs. 4.0 months, p<0.0001).  
Toms et al. (2019) reported that 86% of the patients in the Optune® plus TMZ group had a compliance 
rate of at least 50% (n=388), and 10% of the patients had a compliance rate of at least 90% (n=10). In 
Kanner et al. (2014), 77% of the patients (n=92) in the Optune® group complied with the treatment at least 
75% of the time. In Mrugala et al. (2014), 44% (n=127) of the patients achieved daily compliance of 
greater than or equal to 75%. 
Summary of findings regarding effects on overall survival: There is a preponderance of evidence 
from two primary RCTs, one interim analysis, and four post-hoc analyses from these RCTs that Optune® 
increases median overall survival among adults with GBM. 
Figure 2. Effect of Optune® on Median Overall Survival Among Adults with GBM 
 
Progression-Free Survival  
Four studies examined whether the length of progression-free survival differed between intervention and 
control groups. Progression-free survival measures the length of time during which the GBM does not get 
worse. In the EF-11 RCT (Stupp et al., 2012), which analyzed outcomes for an ITT population with 
recurrent GBM, the difference in the progression-free survival rate at 6 months between the groups who 
received Optune® (intervention) and active chemotherapy (control) was not statistically significant (21.4% 
[intervention] and 15.1% [control], p=0.13). The EF-14 RCT (Stupp et al., 2017) found that median 
progression-free survival differed between people with newly diagnosed GBM who received Optune® and 
TMZ versus TMZ alone (6.7 months among patients receiving Optune® and TMZ and 4.0 months among 
patients receiving TMZ alone, respectively, p<0.001). Similar results were shown in the trial’s interim 
analysis (Stupp et al., 2015), which looked at progression-free survival in the ITT population. Median 
progression-free survival was 7.1 months in the intervention group and 4.0 months in the control group. 
Toms et al. (2019) looked at EF-14 RCT participants whose treatment compliance rate was at least 50%; 
they concluded that those participants in the Optune® plus TMZ group had longer median progression-
free survival than the TMZ only group, with maximal survival benefit in the >90% compliance group. 
Median progression-free survival in the Optune® plus TMZ group with >90% compliance was 8.2 months 
compared to 4.0 months in the TMZ alone group with >90% compliance. 
Summary of findings regarding effects on progression-free survival: There is limited evidence from 
two primary RCTs, one interim analysis, and one post-hoc analysis from these RCTs that Optune® 
increases median progression-free survival among adults with newly diagnosed GBM. 
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Figure 3. Effect of Optune® on Median Progression-Free Survival Among Adults with Newly Diagnosed 
GBM 
 
 
Quality of Life and Functional Status 
Three studies examined the impact of Optune® on quality of life and functional status measures. The EF-
11 RCT concluded that participants receiving Optune® had higher cognitive, emotional, and role 
functioning than participants receiving chemotherapy. However, the groups showed no numerical 
differences in global health (i.e., a composite quality of life measure) and social functioning, and the 
authors concluded that physical functioning “may be slightly worse” among Optune® users than 
chemotherapy users. None of the functional status measures assessed by this RCT were tested 
statistically; instead, the authors drew conclusions based on examining the prevalence rates between the 
two groups (Stupp et al., 2012). 
The interim analysis of the EF-14 RCT (Zhu et al., 2017) showed no preliminary evidence that quality of 
life, cognitive status, and functional status were adversely affected by the continuous use of Optune®. 
Results from a secondary analysis of the same RCT (Taphoorn et al., 2018) concluded that quality of life 
measures did not differ significantly between the groups. Deterioration-free survival — defined as the time 
to a greater than 10-point deterioration in health-related quality of life scores from baseline without a 
subsequent 10-point improvement in scores, progressive disease, or death — was longer in the Optune® 
group for global health status, physical functioning, emotional functioning, pain, and leg weakness (all p-
values <0.01). 
Summary of findings regarding effects of Optune® use on quality of life and functional status 
measures: There is inconclusive evidence from one primary RCT, one interim analysis of an RCT, and 
one secondary analysis of an RCT regarding whether Optune® improves quality of life and functional 
status measures compared to usual care for GBM. 
Figure 4. Effect of Optune® on Quality of Life and Functional Status 
 
Harms 
Four studies formally assessed harms associated with Optune®: the EF-11 RCT; the PRiDe analysis, 
which compared outcomes of patients in a “real world” setting to those in both the intervention and 
comparison groups in the EF-11 RCT; the EF-14 RCT; and the secondary analysis of the EF-14 RCT 
done by Taphoorn et al. (2018). Additional articles discussed harms, but they either did not designate 
them as primary or secondary endpoints (i.e., the studies were not appropriately powered to test for 
differences in harms between groups) or did not provide the results of statistical tests of the significance 
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of differences between the intervention and comparison groups. Because of this, these studies were 
excluded in CHBRP’s analysis on harms. 
The EF-11 RCT (Stupp et al., 2012) found that 6% of the patients treated with Optune® experienced a 
severe adverse event, compared to 16% of those treated with chemotherapy (p=0.022). The PRiDe 
analysis (Mrugala et al., 2014) found that “No new adverse events were detected in PRiDe compared to 
those found in EF-11.” Contact dermatitis was the most common harm found in the EF-11 RCT (16.0% of 
the patients treated with Optune®), and “skin reaction” was the most common harm found in the PRiDe 
analysis (24.3% of the patients treated with Optune® in PRiDe). These harms were caused by the 
device’s transducer patches. Although the EF-14 RCT (Stupp et al., 2017) found that mild to moderate 
skin toxicity existed underneath the transducer patches in 52% of the patients who received Optune®, the 
researchers did not find a statistically significant difference in the overall incidence, distribution, or 
severity of adverse events between the intervention and control groups. The analysis done by Taphoorn 
et al. (2018) found that more people in the Optune® plus TMZ group reported “itchy skin” as a side effect 
compared to those in the TMZ alone group; this side effect was significantly worse at 3, 6, and 9 months 
of treatment, but not at 12 months.  
Summary of findings regarding harms associated with Optune® use: There is limited evidence from 
two primary RCTs and two secondary analyses that using Optune® is associated with skin irritation but is 
not associated with more frequent or severe harms than usual care for GBM. 
Figure 5. Harms of Optune® 
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BENEFIT COVERAGE, UTILIZATION, AND COST IMPACTS 
As discussed in the Policy Context section, SB 746 would require DMHC-regulated health plans and CDI-
regulated policies that cover chemotherapy or radiation therapy for the treatment of cancer to also cover 
FDA-approved anticancer medical devices that are to be used outside of a medical facility.  
This section reports the potential incremental impacts of SB 746 on estimated baseline benefit coverage, 
utilization, and overall cost. As mentioned in the Policy Context section, CHBRP found only one such 
device, Optune®, which is used for the treatment of glioblastoma multiforme (GBM), a type of brain 
cancer, that is currently approved by the FDA (as of March 2019).28 It is possible that other devices will 
become available in the future, or that Optune® will be approved for the treatment of other types of 
cancer. For this analysis, CHBRP focused on the use of Optune® to treat GBM because it is the only 
anticancer device on the market today that meets the specifications of SB 746. According to the bill, 
“anticancer medical device” means a medical device, including component parts, services, and supplies 
necessary for the effective use of the device.  
Key Assumptions  
• SB 746 would not impact any form of cost sharing, such as deductibles, copayments, and 
coinsurance. 
• SB 746 would not affect plan or insurer use of utilization management, such as prior authorization 
requirements and review for medical necessity.  
For further details on the underlying data sources and methods used in this analysis, please see 
Appendix C. 
Baseline and Postmandate Benefit Coverage 
Currently, among enrollees with health insurance that would be subject to SB 746, 91% have coverage 
for Optune®. Current coverage of Optune® was determined by a survey of the largest (by enrollment) 
providers of health insurance in California. Responses to this survey represent 82% of enrollees with 
private market health insurance that can be subject to state mandates. All health plans and policies that 
cover Optune® do so under the durable medical equipment (DME) benefit, and any cost-sharing 
requirements for DME, such as deductibles, copayments, and coinsurance, apply to Optune®. Some 
insurers also require review for medical necessity or prior authorization. One plan indicated that its 
coverage was for newly diagnosed cases of GBM only and that other uses were considered 
investigational. CHBRP assumes that these benefit designs would not change under SB 746 and that 
those plans and insurers without coverage would need to provide coverage postmandate (see estimates 
in Table 1). CHBRP confirmed similar impacts on other market segments such as CalPERS and several 
of the larger (by enrollment) Medi-Cal MCPs. CHBRP assumes that all health plans and policies will be in 
compliance with the proposed mandate. 
Baseline and Postmandate Utilization 
CHBRP is not able to quantify the baseline utilization data due to limitations in health insurance claims 
data. CHBRP estimated the baseline and postmandate utilization based on the existing literature and 
                                                     
28 Personal communication with Jonathan S. Helfgott, March 2019. 
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content experts’ input instead. As mentioned in the Background section, it is estimated that there will be 
1,200 (3.21 cases per 100,000 people) new cases of GBM in California each year, mostly among adults 
aged 65 and above (ACS, 2019; Ostrom et al., 2018). SB 746 would not affect coverage for most older 
adults with GBM because most have coverage through the Medicare program, which is not subject to 
state benefit mandates. Based on a published study (Onken et al., 2018, 30% of patients with a primary 
diagnosis of GBM were informed about TTFields (Optune®). Among patients informed about Optune®, the 
acceptance rate was 36% (Onken et al., 2018). Based on the age-adjusted incidence rate, CHBRP 
estimated that there will be 56 adult enrollees with coverage subject to SB 746 using Optune® in the 
baseline year. Even with insurance coverage for Optune®, patients may decide not to use it due to factors 
including necessity of head shaving, frequent patch change every 3–4 days, weight of the device and 
need for spare batteries, visibility of the patches, increased sweating in warm air temperatures, and 
mobility issues while carrying the device (Onken et al., 2018; Topfer and Farrah, 2018). Patients who live 
longer due to the use of Optune® may incur use of other services (e.g., chemotherapy), but CHBRP did 
not include those in the utilization and cost impact estimates due to limitations of current claims data. 
Only 29 unique users were identified in Milliman’s 2016 Consolidated Health Cost Guidelines™ Sources 
Database (CHSD) and the 2016 MarketScan® Commercial Claims and Encounters Databases; the 
sample sizes are too small to develop a reliable estimate.  
Postmandate, based on CHBRP expert opinion, it is estimated that the utilization of Optune® may 
increase 10% due to increased awareness and acceptance of the treatment by both providers and 
patients, which would result in five more users. Physicians who currently prescribe Optune® must receive 
training and certification to do this, although the process is very manageable (Topfer and Farrah, 2018). 
See estimates in Table 1. 
Baseline and Postmandate Per-Unit Cost  
The cost of Optune® is $21,000 per user per month, which includes component parts, services, and 
supplies necessary for the effective use of the device (Topfer and Farrah, 2018). Based on Milliman’s 
2016 CHSD and the 2016 MarketScan® Commercial Claims and Encounters Databases, the average cost 
paid by health plans and insurers is $18,624 per month per user. The average length of Optune® use is 
5.2 months per user (Topfer and Farrah, 2018). CHBRP estimates the average cost will be $96,845 per 
user. Since the expected utilization increase is minimal and Optune® unit cost has remained constant 
since it came to the market, CHBRP assumes SB 746 would have no impact on per-unit cost 
postmandate. See estimates in Table 1. 
Baseline and Postmandate Expenditures 
Table 4 and Table 5 present baseline and postmandate expenditures by market segment for DMHC-
regulated plans and CDI-regulated policies. The tables present per member per month (PMPM) 
premiums, enrollee expenses for both covered and noncovered benefits, and total expenditures 
(premiums as well as enrollee expenses). 
SB 746 would increase total net annual expenditures by $648,000 or 0.0004% for enrollees with DMHC-
regulated plans and CDI-regulated policies. This is due to a $717,000 increase in total health insurance 
premiums paid by employers and enrollees for newly covered benefits, adjusted by an increase in 
enrollee expenses for covered and/or noncovered benefits. 
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Premiums 
Changes in premiums as a result of SB 746 would vary by market segment. Note that such changes are 
related to the number of enrollees (see Table 1, Table 4, and Table 5) with health insurance that would be 
subject to SB 746.  
The mandate is estimated to increase premiums by about $717,000. The distribution of the impact on 
premiums is as follows: 
• Total premiums for private employers purchasing group health insurance are estimated to 
increase by $377,000 or 0.0004%. 
• Total employer premium expenditures for CalPERS HMOs are estimated to increase by $11,000, 
or 0.0004%. 
Of the amount CalPERS would pay in additional total premiums, about $9,000 would be the cost borne by 
the General Fund for CalPERS HMO members who are state employees or their dependents. 
• Enrollee contributions toward premiums for group insurance are estimated to increase by 
$78,000, or 0.0005%. 
• Total premiums for purchasers of individual market health insurance are estimated to increase by 
$73,000, or 0.0006%. 
The premium changes among privately funded market segments are less than $0.01 PMPM. Among 
publicly funded DMHC-regulated health plans, the impacts for DMHC-regulated enrollees associated with 
Medi-Cal MCPs and with CalPERS are also very similar, less than $0.01 PMPM.  
CHBRP estimates there will be a $177,000 increase in expenditures for the 7.6 million Medi-Cal 
beneficiaries enrolled in DMHC-regulated plans. 
Enrollee Expenses 
SB 746–related changes in enrollee expenses for covered benefits (e.g., deductibles, copayments) and 
enrollee expenses for noncovered benefits would vary by market segment. Note that such changes are 
related to the number of enrollees (see Table 1,Table 4, and Table 5) with health insurance that would be 
subject to SB 746 and expected to use Optune® during the year after enactment. 
CHBRP projects no change to copayments or coinsurance for those with coverage but does project an 
increase in utilization of Optune® and therefore an increase in overall enrollee cost sharing. However, 
health plans that do not currently cover Optune® can set cost-sharing requirements once coverage is 
mandated (e.g., they may require higher cost-sharing amounts).  
It is possible that some enrollees premandate have incurred expenses related to use of Optune® for which 
coverage was denied, but CHBRP cannot estimate the frequency with which such situations occur and so 
cannot offer a calculation of impact. In some of these cases, it is possible the device would be provided 
through the manufacturer’s patient assistance program. 
Potential Cost Offsets or Savings in the First 12 Months After Enactment 
CHBRP does not project any cost offsets or savings in health care that would result because of the 
enactment of provisions in SB 746 since Optune® is used to complement other standard treatments. 
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Patients who live longer due to the use of Optune® may incur additional medical treatment costs 
(Bernard-Arnoux et al., 2016), but CHBRP did not include those in the cost impact estimates due to 
limitations of the claims data mentioned above. French researchers examined the cost effectiveness of 
Optune®; they found that adding TTFields therapy to standard of care resulted in increases of life 
expectancy of 4.08 months (0.34 Life Year Gained [LYG]) and cost (in euros) of €185,476 per patient 
(Bernard-Arnoux et al., 2016), with the Incremental Cost Effectiveness Ratio (ICER) of €549,909/LYG. 
The most influential factor on the ICER was the cost of TTFields therapy (€21,000 per month), followed 
equally by additional monthly treatment costs (€1,532 to €3,572) for both prolonged overall survival and 
progression-free survival periods. The probabilistic sensitivity analysis showed a 95% conﬁdence interval 
of the ICER of €447,017/LYG to €745,805/LYG with 0% chance to be cost-effective.  
Postmandate Administrative Expenses and Other Expenses 
CHBRP estimates that the increase in administrative costs of DMHC-regulated plans and CDI-regulated 
policies will remain proportional to the increase in premiums. CHBRP assumes that if health care costs 
increase as a result of increased utilization or changes in unit costs, there is a corresponding proportional 
increase in administrative costs. CHBRP assumes that the administrative cost portion of premiums is 
unchanged. All health plans and insurers include a component for administration and profit in their 
premiums. 
Other Considerations for Policymakers 
In addition to the impacts a bill may have on benefit coverage, utilization, and cost, related considerations 
for policymakers are discussed below. 
Postmandate Changes in the Number of Uninsured Persons29 
Because the change in average premiums does not exceed 1% for any market segment (see Table 1, 
Table 4, and Table 5), CHBRP would expect no measurable change in the number of uninsured persons 
due to the enactment of SB 746. 
Changes in Public Program Enrollment 
CHBRP estimates that the mandate would produce no measurable impact on enrollment in publicly 
funded insurance programs due to the enactment of SB 746. 
How Lack of Benefit Coverage Results in Cost Shifts to Other Payers 
In general, CHBRP assumes that in some cases, patients’ use of Optune® will not be covered by their 
health plan or policy (i.e., coverage will be denied because the device was not deemed to be medically 
necessary). However, no cost shift to other payers is expected due to the existence of the manufacturer’s 
patient assistance program.  
                                                     
29 See also CHBRP’s Uninsured: Criteria and Methods for Estimating the Impact of Mandates on the Number of 
Individuals Who Become Uninsured in Response to Premium Increases (December 2015), available at 
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.  
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Table 4. Baseline Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2020 
  DMHC-Regulated  CDI-Regulated    
  Privately Funded Plans 
(by Market) (a) 
 Publicly Funded Plans  Privately Funded Plans 
(by Market) (a) 
   
  Large 
Group 
Small 
Group 
Individual  CalPERS 
HMOs (b) 
MCMC 
(Under 65) 
(c) 
MCMC 
(65+) (c) 
 Large 
Group 
Small 
Group 
Individual   Total 
Enrollee counts               
 
Total enrollees in 
plans/policies 
subject to state 
mandates (d) 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
  
24,490,000 
 
Total enrollees in 
plans/policies 
subject to SB 746  10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
  
24,490,000 
Premiums                        
 
Average portion 
of premium paid 
by employer $555.35 $341.99 $0.00  $493.71 $268.13 $694.55  $710.92 $462.84 $0.00   $118,029,198,000 
 
Average portion 
of premium paid 
by employee $39.66 $205.44 $437.39  $94.04 $0.00 $0.00  $250.37 $202.64 $475.67   $26,521,718,000 
 Total premium $595.01 $547.43 $437.39  $587.76 $268.13 $694.55  $961.29 $665.48 $475.67   $144,550,916,000 
Enrollee expenses                        
 
For covered 
benefits 
(deductibles, 
copays, etc.) $46.18 $121.03 $115.38  $48.33 $0.00 $0.00  $162.44 $186.84 $168.51   $14,750,880,000 
 
For noncovered 
benefits (e) $0.00 $0.00 $0.00  $0.00 $0.00 $0.00  $0.00 $0.00 $0.00   $0 
 
Total 
expenditures $641.19 $668.46 $552.77  $636.08 $268.13 $694.55  $1,123.73 $852.31 $644.18   $159,301,796,000 
Source: California Health Benefits Review Program, 2019. 
Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state’s health insurance marketplace). 
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(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents. About one in five (20.5%) of these enrollees has a 
pharmacy benefit not subject to DMHC.30 CHBRP has projected no impact for those enrollees. However, CalPERS could, postmandate, require equivalent coverage for all its 
members (which could increase the total impact on CalPERS).  
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who are also Medicare beneficiaries. This population does not include enrollees in COHS. 
(d) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-sponsored health insurance. This group includes 
commercial enrollees (including those associated with Covered California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.31  
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by 
insurance. This only includes those expenses that would be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by 
insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; COHS = County Organized 
Health Systems; DMHC = Department of Managed Health Care; MCMC = Medi-Cal Managed Care. 
 
                                                     
30 For more detail, see Estimates of Pharmacy Benefit Coverage, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php).  
31 For more detail, see Estimates of Sources of Health Insurance in California, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php.  
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Table 5. Postmandate Per Member Per Month Premiums and Total Expenditures by Market Segment, California, 2020 
  DMHC-Regulated  CDI-Regulated   
  Privately Funded Plans 
(by Market) (a) 
 Publicly Funded Plans  Privately Funded Plans 
(by Market) (a) 
  
  Large 
Group 
Small 
Group 
Individual  CalPERS 
HMOs (b) 
MCMC 
(Under  
65) (c) 
MCMC 
(65+) (c) 
 Large 
Group 
Small 
Group 
Individual  Total 
Enrollee counts              
 
Total enrollees in 
plans/policies 
subject to state 
mandates (d) 10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
 
24,490,000 
 
Total enrollees in 
plans/policies 
subject to SB 746  10,565,000 3,099,000 2,184,000 
 
523,000 6,796,000 795,000 
 
318,000 108,000 102,000 
 
24,490,000 
Premiums                       
 
Average portion of 
premium paid by 
employer $0.0020 $0.0015 $0.0000  $0.0018 $0.0011 $0.0091  $0.0169 $0.0016 $0.0000  $566,000 
 
Average portion of 
premium paid by 
employee $0.0001 $0.0009 $0.0027  $0.0003 $0.0000 $0.0000  $0.0060 $0.0007 $0.0027  $152,000 
 Total premium $0.0021 $0.0025 $0.0027  $0.0021 $0.0011 $0.0091  $0.0229 $0.0024 $0.0027  $717,000 
Enrollee expenses                       
 
For covered 
benefits 
(deductibles, 
copays, etc.) $0.0000 -$0.0001 $0.0000  $0.0000 $0.0000 $0.0000  -$0.0176 $0.0000 $0.0000  -$68,000 
 
For noncovered 
benefits (e) $0.0000 $0.0000 $0.0000  $0.0000 $0.0000 $0.0000  $0.0000 $0.0000 $0.0000  $0 
 
Total 
expenditures $0.0021 $0.0024 $0.0027  $0.0021 $0.0011 $0.0091  $0.0053 $0.0024 $0.0027  $649,000 
Percent change                    
 Premiums 0.0004% 0.0005% 0.0006%  0.0004% 0.0004% 0.0013%  0.0024% 0.0004% 0.0006%  0.0005% 
 
Total 
expenditures 0.0003% 0.0004% 0.0005%  0.0003% 0.0004% 0.0013%  0.0005% 0.0003% 0.0004%  0.0004% 
Source: California Health Benefits Review Program, 2019. 
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Notes: (a) Includes enrollees with grandfathered and nongrandfathered health insurance acquired outside or through Covered California (the state’s health insurance marketplace). 
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents. About one in five (20.5%) of these enrollees has a 
pharmacy benefit not subject to DMHC.32 CHBRP has projected no impact for those enrollees. However, CalPERS could, postmandate, require equivalent coverage for all its 
members (which could increase the total impact on CalPERS).  
(c) Medi-Cal Managed Care Plan expenditures for members over 65 include those who are also Medicare beneficiaries. This population does not include enrollees in COHS. 
(d) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in employer-sponsored health insurance. This group includes 
commercial enrollees (including those associated with Covered California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.33  
(e) Includes only those expenses that are paid directly by enrollees or other sources to providers for services related to the mandated benefit that are not currently covered by 
insurance. This only includes those expenses that would be newly covered, postmandate. Other components of expenditures in this table include all health care services covered by 
insurance. 
Key: CalPERS HMOs = California Public Employees’ Retirement System Health Maintenance Organizations; CDI = California Department of Insurance; COHS = County Organized 
Health Systems; DMHC = Department of Managed Health Care; MCMC = Medi-Cal Managed Care. 
 
                                                     
32 For more detail, see Estimates of Pharmacy Benefit Coverage, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php).  
33 For more detail, see Estimates of Sources of Health Insurance in California, available at  http://chbrp.com/analysis_methodology/cost_impact_analysis.php.  
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org 24 
PUBLIC HEALTH IMPACTS 
As discussed in the Policy Context section, SB 746 would require plans and policies that cover 
chemotherapy or radiation therapy for the treatment of cancer to also cover FDA-approved anticancer 
medical devices that are to be used outside of a medical facility. The public health impact analysis 
includes estimated impacts of SB 746 in the short term (within 12 months of implementation) and in the 
long term (beyond the first 12 months postmandate). This section estimates the short-term impact34 of SB 
746 on outcomes such as overall survival rate, progression-free survival rate, quality of life and functional 
status, and adverse events due to Optune®. See Long-Term Impacts for discussion of premature death, 
economic loss, and social determinants of health. 
Estimated Public Health Outcomes 
As presented in the Medical Effectiveness section, CHBRP found a preponderance of evidence that 
persons receiving Optune® have increased overall survival and limited evidence that Optune® increases 
progression-free survival among people with newly diagnosed GBM compared to persons who receive 
standard of care. Findings regarding improvements in functional status and quality of life measurements 
are inconclusive. There is limited evidence that using Optune® does not lead to more frequent or severe 
adverse events than standard of care. 
As presented in the Benefit Coverage, Utilization, and Cost Impacts section, currently there is wide-
spread insurance coverage for Optune®. It is anticipated that due to publicity around the passage of SB 
746 there may be an increase in utilization of Optune® by 10%, leading to an additional five GBM patients 
utilizing Optune® as part of their GBM therapy. The research presented in the Medical Effectiveness 
section indicates that the median increase in survival time for those using Optune® is approximately 5 
months.  
Despite a preponderance of evidence that Optune® is medically effective, CHBRP projects no measurable 
public health impact at the population level due to the small estimated increase in utilization. However, SB 
746 would likely yield increased length of life among the additional five enrollees who would use Optune® 
in the treatment of GBM.  
Potential Harms From SB 746 
When data are available, CHBRP estimates the marginal change in relevant harms associated with 
interventions affected by the proposed mandate. In the case of SB 746, as reported in the Medical 
Effectiveness section, there is no evidence to suggest that an increase in the use of Optune® could result 
in additional harm to enrollees with GBM.  
Impact on Disparities35 
As reported in the Background section, non-Hispanic whites have higher rates of incidence of GBM as 
well as lower 5-year survival rates compared to other racial/ethnic groups (Ostrom et al., 2018). In 
                                                     
34 CHBRP defines short-term impacts as changes occurring within 12 months of bill implementation. 
35. For details about CHBRP’s methodological approach to analyzing disparities, see the Benefit Mandate Structure 
and Unequal Racial/Ethnic Health Impacts document here: 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php. 
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addition, in terms of treatment for GBM, one study found that factors associated with not receiving 
therapy for GBM including being female, black, Hispanic, and of older age (Dressler et al., 2019). 
Racial or ethnic disparities in the prevalence and treatment of GBM exist; however, CHBRP did not find 
evidence to suggest that SB 746 would impact utilization of Optune® differentially by race or ethnicity. 
Despite an estimated increase in utilization of Optune®, CHBRP projects no impact on racial or ethnic 
disparities related to GBM treatment and survival. 
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LONG-TERM IMPACTS 
In this section, CHBRP estimates the long-term impacts,36 defined as those occurring beyond the first 12 
months after implementation, of SB 746. These estimates are qualitative and based on the existing 
evidence available in the literature. CHBRP does not provide quantitative estimates of long-term impacts 
because of unknown improvements in clinical care, changes in prices, implementation of other 
complementary or conflicting policies, and other unexpected factors. 
Long-Term Utilization and Cost Impacts 
Utilization Impacts  
After the estimated increase in utilization in the first 12 months, there is no indication in the research 
literature that the trend of utilization and incidence rate of enrollees with GBM will change over time. 
However, in the long term, it is possible that Optune® could be improved (e.g., become lighter) and have 
wider utilization as the treatment becomes more normalized and patient acceptance increases. In 
addition, as described in the Medical Effectiveness section, there are several preliminary studies 
underway that assess the efficacy and safety of Optune® for other conditions and populations such as 
pediatric GBM, non-small cell lung cancer, pancreatic cancer, ovarian cancer, and cancer that has 
metastasized in the brain from other locations. There may be more anticancer medical devices that come 
to the market in the future. If that happens, the overall utilization of anticancer devices will increase.  
Cost Impacts 
If the utilization of anticancer medical devices increases, CHBRP estimates that the cost will go up as 
well. As mentioned above, based on a cost-effectiveness study of Optune® conducted in France, the most 
influential factor on the Incremental Cost Effectiveness Ratio (ICER) for Optune® was the cost of the 
device (€21,000), followed equally by additional monthly treatment costs (€1,532 to €3,572) for both 
prolonged overall survival and progression-free survival periods.  
Long-Term Public Health Impacts 
Some interventions in proposed mandates provide immediate measurable impacts (e.g., maternity service 
coverage or acute care treatments) while other interventions may take years to make a measurable 
impact (e.g., coverage for tobacco cessation or vaccinations). When possible, CHBRP estimates the long-
term effects (beyond 12 months postmandate) to the public’s health that would be attributable to the 
mandate, including impacts on social determinants of health, premature death, and economic loss.  
In the case of SB 746, CHBRP estimates that although there may not be any change in insurance 
coverage for Optune®, utilization of Optune® would increase 10% due to the publicity and increased 
awareness surrounding the passage of the legislation. As referenced above, Optune® could have wider 
utilization in the long term. CHBRP did not include these studies in its review as Optune® is not currently 
approved for treatment of other cancers. In addition, it is uncertain what impact Optune® could have on 
survival rates for these cancers, yet there is potential that it will extend survival time, as it does for GBM 
patients, but it is also possible that it will not be as effective with other types of cancers. Additionally, it is 
                                                     
36 See also CHBRP’s Criteria and Guidelines for the Analysis of Long-Term Impacts on Healthcare Costs and Public 
Health, available at http://www.chbrp.org/analysis_methodology/cost_impact_analysis.php.  
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unknown to what extent there will be other anticancer medical devices that are approved by the FDA in 
the future that will have the potential to significantly impact the public’s health.  
Therefore, the potential long-term impact of SB 746 is unknown, although it stands to reason that there is 
the potential for a larger impact in the long-term should Optune® be FDA-approved to treat other cancers 
and if the FDA approves other anticancer medical devices that are effective at treating cancer. 
Impacts on Premature Death and Economic Loss 
Premature death 
Premature death is often defined as death occurring before the age of 75 years (Cox, 2006).37 In 
California, it is estimated that there are nearly 102,000 premature deaths each year, accounting for about 
1.9 million years of potential life lost (YPLL) (CDPH, 2009). Cancer represents the greatest contributor to 
premature death in California, with 21.1% of all YPLL attributable to cancer (CDPH, 2009). It is estimated 
that in California in 2007, the YPLL due to cancer was 1,209 per 100,000 population per year, 
corresponding to an annual state total of nearly 200,000 YPLL (CDPH, 2009). Although incidence rates of 
brain and other CNS tumors are low compared to other cancers, the mortality rates are much higher, 
especially for GBM (Rouse et al., 2016; Ostrom et al., 2018). In addition, the mean YPLL for brain and 
other CNS tumors are higher compared to other common cancers (Rouse et al., 2016).  
Despite a preponderance of evidence that Optune® is medically effective, CHBRP projects no measurable 
impact in premature death at the population level due to the small estimated increase in utilization and 
survival time. However, SB 746 would likely yield an increase in survival time of 5 months for the 
additional five enrollees who would use Optune® in the treatment of GBM, leading to an overall increase 
in survival of 25 months. Future reductions in premature death may be even higher if Optune® is found to 
be effective in treating other types of cancers or if other anticancer medical devices are approved by the 
FDA. 
Economic loss 
Economic loss associated with disease is generally presented in the literature as an estimation of the 
value of the YPLL in dollar amounts (i.e., valuation of a population’s lost years of work over a lifetime). In 
addition, morbidity associated with the disease or condition of interest can also result in lost productivity 
by causing a worker to miss days of work due to illness or acting as a caregiver for someone else who is 
ill. 
SB 746 would likely yield an increase in survival time of 5 months for the additional five enrollees who 
would use Optune® in the treatment of GBM. As the majority of the population impacted by SB 746 are of 
working age, it is likely that this increase in survival time may lead to an increase in productivity and a 
decrease in economic loss associated with GBM. Similarly to reduction in premature death, in the long 
term, there is a possibility that SB 746 could have an even larger impact on a reduction in economic loss 
should Optune® be approved for other types of cancers or if other effective anticancer medical devices 
are approved by the FDA. 
 
                                                     
37 The overall impact of premature death due to a particular disease can be measured in years of potential life lost 
prior to age 75 and summed for the population (generally referred to as “YPLL”) (Cox, 2006). For more information 
about CHBRP’s public health methodology, see 
http://chbrp.com/analysis_methodology/public_health_impact_analysis.php.  
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APPENDIX A  TEXT OF BILL ANALYZED 
On February 25, 2019, the California Senate Committee on Health requested that CHBRP analyze SB 
746. 
 
SENATE BILL No. 746 
 
Introduced by Senator Bates 
(Coauthor: Senator Wilk) 
 
February 22, 2019 
 
An act to add Section 1367.667 to the Health and Safety Code, and to add Section 10123.837 to 
the Insurance Code, relating to health care coverage. 
 
LEGISLATIVE COUNSEL'S DIGEST 
 
SB 746, as introduced, Bates. Health care coverage: anticancer medical devices. 
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure 
and regulation of health care service plans by the Department of Managed Health Care, and makes 
a willful violation of the act a crime. Existing law requires health care service plan contracts and 
health insurance policies to cover certain medical services for particular types of cancer, including 
the screening, diagnosis, and treatment of breast cancer, and the screening and diagnosis of prostate 
cancer, if the contract or policy was issued, amended, or renewed after the applicable date. 
 
This bill would require health care service plan contracts and health insurance policies issued, 
amended, or renewed on or after January 1, 2020, that cover chemotherapy or radiation therapy 
for the treatment of cancer to also cover anticancer medical devices. The bill would define 
“anticancer medical device” as a medical device that has been approved for marketing by the 
federal Food and Drug Administration or is exempt from that approval, is primarily designed to 
be used outside of a medical facility, and has been prescribed by an authorized provider upon the 
provider’s determination that the device is medically reasonable and necessary for the treatment 
of the patient’s cancer. Because a violation of this bill’s provisions by a health care service plan 
would be a crime, the bill would impose a state-mandated local program. 
 
The California Constitution requires the state to reimburse local agencies and school districts for 
certain costs mandated by the state. Statutory provisions establish procedures for making that 
reimbursement. 
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This bill would provide that no reimbursement is required by this act for a specified reason. 
 
DIGEST KEY 
Vote: majority   Appropriation: no   Fiscal Committee: yes   Local Program: yes   
 
BILL TEXT 
THE PEOPLE OF THE STATE OF CALIFORNIA DO ENACT AS FOLLOWS: 
SECTION 1. 
Section 1367.667 is added to the Health and Safety Code, immediately following Section 
1367.665, to read: 
1367.667. (a) Every health care service plan contract issued, amended, or renewed in this state 
on or after January 1, 2020, that provides coverage for chemotherapy or radiation therapy for the 
treatment of cancer, shall also provide coverage for anticancer medical devices. 
(b) For purposes of this section, “anticancer medical device” means a medical device, including 
component parts, services, and supplies necessary for the effective use of the device, that meets 
all of the following criteria: 
(1) The device has been cleared or approved for marketing by the federal Food and Drug 
Administration, if that clearance or approval is required by law. 
(2) The device is primarily and substantially designed for use outside of a medical treatment 
facility, or use for which reimbursement is not ordinarily provided as incident to a provider’s 
professional service or as part of a provider’s fee for service. 
(3) The device is prescribed by a provider authorized to prescribe that device for the treatment of 
cancer, upon a determination by the provider that the device is medically reasonable and 
necessary for the treatment of the patient. 
SEC. 2. 
Section 10123.837 is added to the Insurance Code, immediately following Section 10123.835, to 
read: 
10123.837. (a) Every policy of disability insurance that covers hospital, medical, or surgical 
expenses that is issued, amended, or renewed in this state on or after January 1, 2020, and 
provides coverage for chemotherapy or radiation therapy for the treatment of cancer, shall also 
provide coverage for anticancer medical devices. 
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(b) For purposes of this section, “anticancer medical device” means a medical device, including 
component parts, services, and supplies necessary for the effective use of the device, that meets 
all of the following criteria: 
(1) The device has been cleared or approved for marketing by the federal Food and Drug 
Administration, if that clearance or approval is required by law. 
(2) The device is primarily and substantially designed for use outside of a medical treatment 
facility, or use for which reimbursement is not ordinarily provided as incident to a provider’s 
professional service or as part of a provider’s fee for service. 
(3) The device is prescribed by a provider authorized to prescribe that device for the treatment of 
cancer, upon a determination by the provider that the device is medically reasonable and 
necessary for the treatment of the patient. 
SEC. 3. 
No reimbursement is required by this act pursuant to Section 6 of Article XIII B of the California 
Constitution because the only costs that may be incurred by a local agency or school district will 
be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or 
changes the penalty for a crime or infraction, within the meaning of Section 17556 of the 
Government Code, or changes the definition of a crime within the meaning of Section 6 of 
Article XIII B of the California Constitution. 
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APPENDIX B  LITERATURE REVIEW METHODS 
This appendix describes methods used in the medical effectiveness literature review conducted for this 
report. A discussion of CHBRP’s system for grading evidence, as well as lists of MeSH Terms, publication 
types, and keywords, follows. 
Studies of the effects of Studies of Optune® were identified through searches of PubMed, the Cochrane 
Library, Web of Science, Embase, and Scopus.  
The search was limited to abstracts of studies published in English. The medical effectiveness search 
was limited to studies published from 2010 to present because Optune® did not receive FDA approval 
until 2011. As discussed previously, SB 746 would only require coverage for anticancer medical devices 
approved by the FDA. 
Reviewers screened the title and abstract of each citation retrieved by the literature search to determine 
eligibility for inclusion. The reviewers acquired the full text of articles that were deemed eligible for 
inclusion in the review and reapplied the initial eligibility criteria. 
The literature review returned abstracts for 288 articles, of which 17 were reviewed for inclusion in this 
report. A total of nine articles were included in the medical effectiveness review for SB 746. 
Evidence Grading System 
In making a “call” for each outcome measure, the medical effectiveness lead and the content expert 
consider the number of studies as well the strength of the evidence. Further information about the criteria 
CHBRP uses to evaluate evidence of medical effectiveness can be found in CHBRP’s Medical 
Effectiveness Analysis Research Approach.38 To grade the evidence for each outcome measured, the 
team uses a grading system that has the following categories: 
• Research design; 
• Statistical significance; 
• Direction of effect;  
• Size of effect; and 
• Generalizability of findings.  
The grading system also contains an overall conclusion that encompasses findings in these five domains. 
The conclusion is a statement that captures the strength and consistency of the evidence of an 
intervention’s effect on an outcome. The following terms are used to characterize the body of evidence 
regarding an outcome: 
• Clear and convincing evidence; 
• Preponderance of evidence; 
• Limited evidence; 
• Inconclusive evidence; and  
                                                     
38 Available at: http://chbrp.com/analysis_methodology/medical_effectiveness_analysis.php.  
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org B-2 
• Insufficient evidence. 
A grade of clear and convincing evidence indicates that there are multiple studies of a treatment and that 
the large majority of studies are of high quality and consistently find that the treatment is either effective 
or not effective.  
A grade of preponderance of evidence indicates that the majority of the studies reviewed are consistent in 
their findings that treatment is either effective or not effective.  
A grade of limited evidence indicates that the studies had limited generalizability to the population of 
interest and/or the studies had a fatal flaw in research design or implementation. 
A grade of inconclusive evidence indicates that although some studies included in the medical 
effectiveness review find that a treatment is effective, a similar number of studies of equal quality suggest 
the treatment is not effective. 
A grade of insufficient evidence indicates that there is not enough evidence available to know whether or 
not a treatment is effective, either because there are too few studies of the treatment or because the 
available studies are not of high quality. It does not indicate that a treatment is not effective. 
Search Terms (* indicates truncation of word stem) 
 
Adherence 
 
Remission 
 
Survival 
 
Progression 
 
Mortality 
 
Optune 
 
Tumor Treatment Fields 
 
Tumor-Treatment Fields 
 
Tumor Treating Fields 
 
Tumor-Treating Fields 
 
TTF 
 
NovoTTF 
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APPENDIX C  COST IMPACT ANALYSIS: DATA 
SOURCES, CAVEATS, AND ASSUMPTIONS 
The cost analysis in this report was prepared by the members of the cost team, which consists of CHBRP 
task force members and contributors from the University of California, Los Angeles, and the University of 
California, Davis, as well as the contracted actuarial firm, Milliman, Inc. (Milliman).39  
Information on the generally used data sources and estimation methods, as well as caveats and 
assumptions generally applicable to CHBRP’s cost impact analyses are available on CHBRP’s website.40  
This appendix describes any analysis-specific data sources, estimation methods, caveats, and 
assumptions used in preparing this cost impact analysis. 
Analysis Specific Caveats and Assumptions 
This subsection discusses the caveats and assumptions relevant specifically to an analysis of SB 746. 
CHBRP projects that SB 746:  
• Would not impact any form of cost sharing, such as deductibles, copayments, and coinsurance; 
• Would not affect plan or insurer methods of utilization management that may impact the coverage 
of medical treatments between baseline and postmandate periods, such as use of prior 
authorization requirements and review for medical necessity.  
The following is a description of methodology and assumptions used to develop the estimates of cost 
impacts: 
• The definition of “anticancer medical device” provided in the text of SB 746 was determined to be 
applicable at this time to a single device, Novocure’s Optune®, for the treatment of GBM. This is 
consistent with the bill author’s stated intent. While CHBRP is aware of other anticancer medical 
devices in the product pipeline, none are expected to become available within the timeline of this 
analysis. 
• Optune® is identified by two Healthcare Common Procedure Coding System (HCPCS) codes: 
E0766 (new unit) and A4555 (replacement unit). Monthly rental fees for Optune® include all 
associated maintenance, parts, and services. 
• Milliman extracted claims data for these codes from Milliman’s 2016 Consolidated Health Cost 
Guidelines™ Sources Database (CHSD) and the 2016 MarketScan® Commercial Claims and 
Encounters Databases. These data were used to develop baseline cost-sharing assumptions for 
the Optune® device. The claims data are summarized in Table 6. 
 
 
                                                     
39 CHBRP’s authorizing statute, available at www.chbrp.org/docs/authorizing_statute.pdf, requires that CHBRP use a 
certified actuary or “other person with relevant knowledge and expertise” to determine financial impact. 
40 See 2019 Cost Impact Analyses: Data Sources, Caveats, and Assumptions, available at  
www.chbrp.org/analysis_methodology/cost_impact_analysis.php. 
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Table 6. Optune® Utilization and Cost (2016 CHSD and MarketScan) 
  Distinct Users 
Total 
Utilization 
Average 
Billed 
Average 
Allowed 
Average 
Paid 
Average 
Patient 
Pay 
Optune® 29 105 $21,000.00 $18,624.13 $18,138.79 $485.34 
• CHBRP did not include either offsets or costs of additional services associated with the use of the 
Optune® device. 
• CHBRP relied upon the carrier surveys to determine existing coverage of Optune®. All 
respondents to the survey indicated that Optune® is currently covered, although some noted that 
coverage is subject to a determination of medical necessity or requires preauthorization.  
• Per-unit cost is $21,000 per user per month, which includes component parts, services, and 
supplies necessary for the effective use of the device (Topfer and Farrah, 2018). (This matches 
claims data). 
• The average length of use of Optune® is 5.2 months per user (Topfer and Farrah, 2018).  
• The incidence rate for GBM in the population included in the CHBRP analysis is estimated from 
the incidence rate by age band provided in Ostrom et al. (2018) applied to the age distribution of 
the CHBRP population. The incidence rate estimate excludes any occurrence of GBM in 
members below the age of 18, as they would not be candidates for use of the Optune® device.  
• For patients with a primary diagnosis of GBM, 30% were informed about TTFields (Optune®) 
based on a published study.  
• Acceptance rate among these informed patients was 36% (Onken et al., 2018). 
• CHBRP assumed 0% cost trend and 0% utilization trend for the baseline projection. 
• CHBRP assumed a 10% one-time increase in utilization postmandate due to increased 
awareness and acceptance of the device. 
Determining Public Demand for the Proposed Mandate 
This subsection discusses public demand for the benefits SB 746 would mandate. Considering the criteria 
specified by CHBRP’s authorizing statute, CHBRP reviews public demand for benefits relevant to a 
proposed mandate in two ways. CHBRP: 
• Considers the bargaining history of organized labor; and 
• Compares the benefits provided by self-insured health plans or policies (which are not regulated 
by the DMHC or CDI and therefore not subject to state-level mandates) with the benefits that are 
provided by plans or policies that would be subject to the mandate. 
On the basis of conversations with the largest collective bargaining agents in California, CHBRP 
concluded that unions currently do not include cost-sharing arrangements for anticancer medical devices. 
In general, unions negotiate for broader contract provisions such as coverage for dependents, premiums, 
deductibles, and broad coinsurance levels. Among publicly funded self-insured health insurance policies, 
the preferred provider organization (PPO) plans offered by CalPERS currently have the largest number of 
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enrollees. The CalPERS PPOs currently provide benefit coverage similar to what is available through 
group health insurance plans and policies that would be subject to the mandate. 
To further investigate public demand, CHBRP used a bill-specific coverage survey to ask carriers who act 
as third-party administrators for (non-CalPERS) self-insured group health insurance programs whether the 
relevant benefit coverage differed from what is offered in group market plans or policies that would be 
subject to the mandate. The responses indicated that there were no substantive differences. 
Second Year Impacts on Benefit Coverage, Utilization, and Cost 
As displayed in Table 7, the second year impacts of SB 746 would be substantially the same as the 
impacts in the first year (see Table 1). 
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Table 7. SB 746 Impacts on Benefit Coverage, Utilization, and Cost, 2021 
  Baseline Postmandate Increase/ 
Decrease 
Percentage 
Change 
Benefit coverage 
 Total enrollees with 
health insurance 
subject to state 
benefit mandates 
(a) 24,395,000 24,395,000 0 0% 
 Total enrollees with 
health insurance 
subject to SB 746  24,395,000 24,395,000 0 0% 
 Percentage of 
enrollees with 
coverage for 
mandated benefit 91% 100% 9% 10% 
Utilization and unit cost 
 Utilization per 
1,000 0.012 0.013 0.001 10% 
 Unit cost per month $18,624 $18,624 0 0% 
 Number of 
enrollees using 
mandated benefit 55 61 6 11% 
 Average cost per 
enrollee using 
anticancer medical 
devices 96,845   96,845    0  0% 
Expenditures 
Premiums by payer 
 Private employers 
for group insurance $90,700,422,000 $90,700,797,000 $375,000 0.0004% 
 CalPERS HMO 
employer 
expenditures (c) (b) $3,234,903,000 $3,234,914,000 $11,000 0.0003% 
 Medi-Cal Managed 
Care Plan 
expenditures $29,186,401,000 $29,186,578,000 $177,000 0.0006% 
 Enrollees with 
individually 
purchased 
insurance $13,111,153,000 $13,111,225,000 $72,000 0.0005% 
 Enrollees with 
group insurance, 
CalPERS HMOs, 
Covered California, 
and Medi-Cal 
Managed Care (c) $15,255,718,000 $15,255,795,000 $77,000 0.0005% 
Enrollee expenses 
 For covered 
benefits 
(deductibles, 
copayments, etc.) $15,636,259,000 $15,636,191,000 -$68,000 -0.0004% 
 For noncovered 
benefits (d) (e) $0 $0 $0 0.00% 
Total expenditures $167,124,856,000 $167,125,500,000 $644,000 0.0004% 
Source: California Health Benefits Review Program, 2019. 
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Notes: (a) Enrollees in plans and policies regulated by DMHC or CDI aged 0 to 64 years as well as enrollees 65 years or older in 
employer-sponsored health insurance. This group includes commercial enrollees (including those associated with Covered 
California or CalPERS) and Medi-Cal beneficiaries enrolled in DMHC-regulated plans.41  
(b) Approximately 56.17% of CalPERS enrollees in DMHC-regulated plans are state retirees, state employees, or their dependents. 
About one in five (20.5%) of these enrollees has a pharmacy benefit not subject to DMHC.42 CHBRP has projected no impact for 
those enrollees. However, CalPERS could, postmandate, require equivalent coverage for all its members (which could increase the 
total impact on CalPERS). 
(c) Enrollee premium expenditures include contributions by employees to employer-sponsored health insurance, health insurance 
purchased through Covered California, and contributions to Medi-Cal Managed Care. 
(d) Includes only expenses paid directly by enrollees (or other sources) to providers for services related to the mandated benefit that 
are not currently covered by insurance. This only includes those expenses that would be newly covered postmandate. Other 
components of expenditures in this table include all health care services covered by insurance. 
(e) Although enrollees with newly compliant benefit coverage may have paid for some treatments before SB 746, CHBRP cannot 
estimate the frequency with which such situations may have occurred and therefore cannot estimate the related expense. 
Postmandate, such expenses would be eliminated, though enrollees with newly compliant benefit coverage might, postmandate, 
pay for some treatments for which coverage is denied (through utilization management review), as some enrollees who always had 
compliant benefit coverage may have done and may continue to do, postmandate.  
Key: CalPERS  = California Public Employees’ Retirement System; CDI = California Department of Insurance; DMHC = Department 
of Managed Health Care; HMO = Health Maintenance Organizations 
 
                                                     
41 For more detail, see Estimates of Sources of Health Insurance in California, available at  
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.  
42 For more detail, see Estimates of Pharmacy Benefit Coverage, available at  
http://chbrp.com/analysis_methodology/cost_impact_analysis.php.  
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APPENDIX D  INFORMATION SUBMITTED BY OUTSIDE 
PARTIES 
In accordance with the California Health Benefits Review Program (CHBRP) policy to analyze information 
submitted by outside parties during the first 2 weeks of the CHBRP review, the following parties chose to 
submit information.  
The following information was submitted by the office of Senator Patricia C. Bates in March 2019.  
Bates, Senator Patricia C. Fact Sheet - SB 746: Treatment Coverage for Anticancer Medical Devices. 
Office of Senator Patricia C. Bates. 2019 Mar 1. 
 
Submitted information is available upon request. For information on the processes for submitting 
information to CHBRP for review and consideration please visit www.chbrp.org/requests.html.
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org  
REFERENCES 
Albain KS, Unger JM, Crowley JJ, Coltman CA Jr., Hershman DL. Racial disparities in cancer survival 
among randomized clinical trials patients of the southwest oncology group. Journal of the 
National Cancer Institute. 2009;101:984-992. 
American Cancer Society (ACS). 5-year relative survival, 2008-2014. Based on National Cancer Institute 
Data, 2018. Available at: https://cancerstatisticscenter.cancer.org/#!/data-
analysis/SurvivalByStage. Accessed March 20, 2019. 
American Cancer Society (ACS). Cancer Statistics Center: California. Available at: 
https://cancerstatisticscenter.cancer.org/?_ga=2.217422358.1212783208.1552521849-
84744138.1541805237#!/state/California. Accessed March 19, 2019. 
American Cancer Society (ACS). Survival rates for selected brain and spinal cord tumors. November 7, 
2017. Available at: https://www.cancer.org/cancer/brain-spinal-cord-tumors-adults/detection-
diagnosis-staging/survival-rates.html. Accessed March 19, 2019. 
Bernard-Arnoux F, Lamure M, Ducray F, Aulagner G, Honnorat J, Armoiry X. The cost-effectiveness of 
tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro-Oncology. 
2016;18(8):1129-1136. 
Bohn A, Braley A, de la Vega PR, Zevallos JC, Barengo NC. The association between race and survival 
in glioblastoma patients in the US: A retrospective cohort study. PloS One. 
2018;21:13(6):e0198581. 
California Cancer Registry (CCR). California Cancer Facts and Figures, 2017. Available at: 
https://www.cancer.org/content/dam/cancer-org/online-documents/en/pdf/reports/california-facts-
figures-2017.pdf. Accessed March 19, 2019. 
California Department of Public Health (CDPH). Center for Health Statistics and Informatics Death Data 
Trend Summary: Premature Mortality Trends 2000-2007. June 2009. Available at: 
http://www.cdph.ca.gov/programs/ohir/Pages/YPLL2007Main.aspx. Accessed December 2011. 
Centers for Disease Control and Prevention. NCHHSTP Social Determinants of Health. Frequently Asked 
Questions. Page last reviewed: March 10, 2014. Available at: 
http://www.cdc.gov/nchhstp/socialdeterminants/faq.html. Accessed August 27, 2015. 
Cox D. Premature Mortality in California, 2004. Center for Health Statistics. December 2006. Available at: 
http://www.cdph.ca.gov/pubsforms/Pubs/OHIRprematuremortality2004.pdf. Accessed November 
2011. 
Dressler EV, Liu M, Garcia CR, Dolecek TA, Pittman T, Huang B, Villano JL. Patterns and disparities of 
care in glioblastoma. Neuro-Oncology Practice. 2018;6(1):37-46. 
Drexell Hunter Boggs. A Pilot and Feasibility Trial to Determine the Rate of the Brain Relapse in Small 
Cell Lung Cancer (SCLC) Patients With Brain Metastases Treated With Stereotactic 
Radiosurgery (SRS) Followed by Tumor Treating Fields (TTF). NLM identifier: NCT03488472. 
Available at: 
https://clinicaltrials.gov/ct2/show/NCT03488472?term=TTFields&cond=Brain+Metastases&rank=
3. Accessed April 1, 2019. 
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org  
Gittleman H, Boscia A, Ostrom QT, Truitt G, Fritz Y, Kruchko C, Barnholtz-Sloan JS. Survivorship in 
adults with malignant brain and other central nervous system tumor from 2000–2014. Neuro-
Oncology. 2018;20(suppl_7):vii6-16. 
Green AL, Mulcahy Levy JM, Vibhakar R, et al. Tumor treating fields in pediatric high-grade glioma. 
Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric 
Neurosurgery. 2017;33(7):1043-1045. 
Kanner AA, Wong ET, Villano JL, Ram Z. Post Hoc analyses of intention-to-treat population in phase III 
comparison of NovoTTF-100A system versus best physician's choice chemotherapy. Seminars in 
Oncology. 2014;41 Suppl 6:S25-34. 
Kesari S, Ram Z. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at 
first recurrence: a post hoc analysis of the EF-14 trial. CNS Oncology. 2017;6(3):185-193. 
Killion JA, Giddings BM, Chen Y, et al. Cancer in California, 1988-2015. Sacramento, CA: California 
Department of Public Health, Chronic Disease Surveillance and Research Branch, April 2018. 
Available at: https://www.ccrcal.org/retrieve-data/data-for-the-public/cancer-statistics-and-
reports/. Accessed March 19, 2019. 
Kinzel A, Ambrogi M, Varshaver M, Kirson ED. Tumor treating fields for glioblastoma treatment: patient 
satisfaction and compliance with the second-generation Optune® system. Clinical Medicine 
Insights: Oncology. 2019;13:1179554918825449. 
Mandel J, Youssef M, Nam JY, Wu J, Liu DD, Bondy M, De Groot J. Effect of Health Disparities on 
Overall Survival of Patients with Glioblastoma. Journal of Neuro-Oncology. 2019.  
Meropol NJ, Schulman KA. Cost of cancer care: Issues and implications. Journal of Clinical Oncology. 
2007;25:180-186. 
Mrugala MM, Engelhard HH, Dinh Tran D, et al. Clinical practice experience with NovoTTF-100A system 
for glioblastoma: The Patient Registry Dataset (PRiDe). Seminars in Oncology. 2014;41 Suppl 
6:S4-s13. 
National Cancer Institute (NCI). Understanding Cancer: Cancer Disparities. October 2016. Available at: 
www.cancer.gov/about-cancer/understanding/disparities. Accessed April 19, 2019.  
National Comprehensive Cancer Network (NCCN). Central Nervous System Cancers (Version 1.2019). 
Available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed April 16, 
2019.  
Novocure Ltd. Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating 
Fields (TTFields) (150kHz) for 1-10 Brain Metastases From Non-small Cell Lung Cancer 
(NSCLC). NLM identifier: NCT02831959. Available at: 
https://clinicaltrials.gov/ct2/show/NCT02831959?term=TTFields&cond=Brain+Metastases&rank=
1. Accessed April 1, 2019. 
Office of Disease Prevention and Health Promotion. Healthy People 2020: Social Determinants of Health. 
Available at: http://www.healthypeople.gov/2020/topics-
objectives/topic/socialdeterminantshealth/addressing-determinants. Accessed February 16, 2016. 
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org  
Onken J, Staub-Bartelt F, Vajkoczy P, Misch M. Acceptance and compliance of TTFields treatment 
among high grade glioma patients. Journal of Neuro-Oncology. 2018;139(1):177-84. 
Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. 
CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in 
the United States in 2010–2014. Neuro-Oncology. 2017;19(suppl_5):v1-88  
Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I/II trial of Tumor Treating Fields 
(TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung 
Cancer (Amsterdam, Netherlands). 2013;81(3):445-450. 
Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopez-Martin J, Kung M. Tumor treating fields in 
combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of 
the PANOVA phase 2 study. Pancreatology: Official Journal of the International Association of 
Pancreatology (IAP). 2019;19(1):64-72. 
Rouse C, Gittleman H, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Years of potential life lost for brain 
and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro-Oncology. 
2015;18(1):70-7. 
Sloane D. Cancer epidemiology in the United States: racial, social, and economic factors. Methods in 
Molecular Biology. 2009;471:65-83. 
Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs 
Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized 
Clinical Trial. JAMA. 2017;318(23):2306-2316. 
Stupp R, Taillibert S, Kanner AA, et al. Maintenance Therapy With Tumor-Treating Fields Plus 
Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 
2015;314(23):2535-2543. 
Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in 
recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. European 
Journal of Cancer (Oxford, England: 1990). 2012;48(14):2192-2202. 
Taphoorn MJB, Dirven L, Kanner AA, et al. Influence of Treatment With Tumor-Treating Fields on Health-
Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of 
a Randomized Clinical Trial. JAMA Oncology. 2018;4(4):495-504. 
Tehranifar P, Neugut AI, Phelan JC, et al. Medical advances and racial/ethnic disparities in cancer 
survival. Cancer Epidemiology, Biomarkers & Prevention. 2009;18:27. 
Toms SA, Kim CY, Nicholas G, Ram Z. Increased compliance with tumor treating fields therapy is 
prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-
14 phase III trial. Journal of Neuro-Oncology. 2019;141(2):467-473. 
Topfer LA, Farrah K. Alternating Electric Fields ("Tumour-Treating Fields") for the Treatment of 
Glioblastoma. CADTH Issues in Emerging Health Technologies. Ottawa (ON): Canadian Agency 
for Drugs and Technologies in Health; Copyright (c) CADTH 2018.  
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org  
Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor Treating Fields in 
combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. 
Gynecologic Oncology. 2018;150(3):471-477. 
Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA: 
A Cancer Journal for Clinicians. 2004;54:78-93. 
Wyatt R, Laderman M, Botwinick L, Mate K, Whittington J. Achieving Health Equity: A Guide for Health 
Care Organizations. IHI White Paper. Cambridge, Massachusetts: Institute for Healthcare 
Improvement; 2016. (Available at ihi.org) 
Zhu JJ, Demireva P, Kanner AA, et al. Health-related quality of life, cognitive screening, and functional 
status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared 
to temozolomide alone in newly diagnosed glioblastoma. Journal of Neuro-Oncology. 
2017;135(3):545-552. 
 
 
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org  
CALIFORNIA HEALTH BENEFITS REVIEW PROGRAM 
COMMITTEES AND STAFF 
A group of faculty, researchers, and staff complete the analysis that informs California Health Benefits 
Review Program (CHBRP) reports. The CHBRP Faculty Task Force comprises rotating senior faculty 
from University of California (UC) campuses. In addition to these representatives, there are other ongoing 
researchers and analysts who are Task Force Contributors to CHBRP from UC that conduct much of 
the analysis. The CHBRP staff coordinates the efforts of the Faculty Task Force, works with Task Force 
members in preparing parts of the analysis, and manages all external communications, including those 
with the California Legislature. As required by CHBRP’s authorizing legislation, UC contracts with a 
certified actuary, Milliman, to assist in assessing the financial impact of each legislative proposal 
mandating or repealing a health insurance benefit.  
The National Advisory Council provides expert reviews of draft analyses and offers general guidance 
on the program to CHBRP staff and the Faculty Task Force. CHBRP is grateful for the valuable 
assistance of its National Advisory Council. CHBRP assumes full responsibility for the report and the 
accuracy of its contents. 
Faculty Task Force 
Janet Coffman, MA, MPP, PhD, Vice Chair for Medical Effectiveness, University of California, San 
Francisco 
Sylvia Guendelman, PhD, LCSW, University of California, Berkeley  
Gerald Kominski, PhD, University of California, Los Angeles 
Sara McMenamin, PhD, Vice Chair for Medical Effectiveness and Public Health, University of California, 
San Diego 
Joy Melnikow, MD, MPH, Vice Chair for Public Health, University of California, Davis 
Jack Needleman, PhD, University of California, Los Angeles 
Ninez Ponce, PhD, University of California, Los Angeles  
Nadereh Pourat, PhD, Vice Chair for Cost, University of California, Los Angeles 
Marilyn Stebbins, PharmD, University of California, San Francisco 
Ed Yelin, PhD, Professor Emeritus, University of California, San Francisco 
Task Force Contributors 
Danielle Casteel, MA, University of California, San Diego 
Shana Charles, PhD, MPP, University of California, Los Angeles,  
and California State University, Fullerton 
Shauna Durbin, MPH, University of California, Davis 
Margaret Fix, MPH, University of California, San Francisco 
Sarah Hiller, MA, University of California, San Diego 
Naomi Hillery, MPH, University of California, San Diego 
Jeffrey Hoch, PhD, University of California, Davis 
Michelle Ko, MD, PhD, University of California, Davis   
Connie Kwong, University of California, San Francisco 
Kevin Lee, PhD Candidate, University of California, Berkeley 
Elizabeth Magnan, MD, PhD, University of California, Davis   
Ying-Ying Meng, PhD, University of California, Los Angeles 
Jacqueline Miller, University of California, San Francisco 
Dominique Ritley, MPH, University of California, Davis 
Dylan Roby, PhD, University of California, Los Angeles, and 
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org  
University of Maryland, College Park 
Riti Shimkhada, PhD, University of California, Los Angeles 
Meghan Soulsby Weyrich, MPH, University of California, Davis  
Steven Tally, PhD, University of California, San Diego  
Christopher Toretsky, MPH, University of California, San Francisco 
Sara Yoeun, University of California, San Diego 
National Advisory Council 
Lauren LeRoy, PhD, Strategic Advisor, L. LeRoy Strategies, Chair 
Stuart H. Altman, PhD, Professor of National Health Policy, Brandeis University, Waltham, MA 
Deborah Chollet, PhD, Senior Fellow, Mathematica Policy Research, Washington, DC 
Allen D. Feezor, Fmr. Deputy Secretary for Health Services, North Carolina Department of Health and 
Human Services, Raleigh, NC 
Charles “Chip” Kahn, MPH, President and CEO, Federation of American Hospitals, Washington, DC 
Jeffrey Lerner, PhD, President and CEO, ECRI Institute Headquarters, Plymouth Meeting, PA 
Donald E. Metz, Executive Editor, Health Affairs, Bethesda, MD 
Dolores Mitchell, (Retired) Executive Director, Group Insurance Commission, Boston, MA 
Marilyn Moon, PhD, Vice President and Director, Health Program, American Institutes for Research,  
Silver Spring, MD 
Carolyn Pare, President and CEO, Minnesota Health Action Group, Bloomington, MN 
Richard Roberts, MD, JD, Professor of Family Medicine, University of Wisconsin-Madison, Madison, WI 
Alan Weil, JD, MPP, Editor-in-Chief, Health Affairs, Bethesda, MD  
CHBRP Staff 
Garen Corbett, MS, Director 
John Lewis, MPA, Associate Director 
Adara Citron, MPH, Principal Policy Analyst 
Karen Shore, PhD, Contractor*  
Karla Wood, Project Analyst 
Ana Ashby, Health Policy Graduate Assistant 
 
*Karen Shore, PhD, is an Independent Contractor with whom CHBRP works to support legislative 
analyses and other special projects on a contractual basis. 
CHBRP is an independent program administered and housed by the University of California, Berkeley, in 
the Office of the Vice Chancellor for Research.  
  
California Health Benefits Review Program 
MC 3116 
Berkeley, CA 94720-3116 
info@chbrp.org   
www.chbrp.org 
(510) 664-5306 
 
Analysis of California Senate Bill 746 
Current as of April 19, 2019 www.chbrp.org  
CHBRP gratefully acknowledges the efforts of the team contributing to this analysis: 
Janet Coffman, MA, MPP, PhD, and Chris Toretsky, MPH of the University of California, San Francisco, 
prepared the medical effectiveness analysis. Stephen L. Clancy, MLS, AHIP, of the University of 
California, Irvine, conducted the literature search. Sara McMenamin, PhD, and Sara Yoeun, of the 
University of California, San Diego, prepared the public health impact analysis. Ying-Ying Meng, PhD of 
the University of California, Los Angeles, prepared the cost impact analysis. Daniel Henry, FSA, MAAA, of 
Milliman, provided actuarial analysis. Mekhail Anwar, MD, PhD, Assistant Professor, Department of 
Radiation Oncology, University of California, San Francisco, provided technical assistance with the 
literature search and expert input on the analytic approach. Karen Shore, PhD, CHBRP contractor 
prepared the Policy Context and synthesized the individual sections into a single report. A subcommittee 
of CHBRP’s National Advisory Council (see final pages of this report) and a member of the CHBRP 
Faculty Task Force, Sylvia Guendelman, PhD, LCSW, of the University of California, Berkeley, reviewed 
the analysis for its accuracy, completeness, clarity, and responsiveness to the Legislature’s request.  
CHBRP assumes full responsibility for the report and the accuracy of its contents. All CHBRP bill 
analyses and other publications are available at www.chbrp.org.  
Garen Corbett, MS 
Director 
 
Please direct any questions concerning this document to: California Health Benefits Review Program; MC 
3116; Berkeley, CA 94720-3116, info@chbrp.org, or www.chbrp.org 
 
